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Introduction to the proceedings
Pharmaceutical care, hospital pharmacy, clinical pharmacy - what is the difference ?
Evidence-Based Pharmaceutical Care was the title of the 27th Annual Symposium of the European Society of Clinical Pharmacy
(ESCP) in Jerusalem in 1998. The effect of patient-focused care on the activities of clinical pharmacists was the title of a lecture at the
3rd Congress of the European Society of Hospital Pharmacy in Edinburgh in the same year [1]. Coincidence? Certainly not. It shows
a new approach to the pharmaceutical profession and a new understanding of the function of the pharmacist, formulated mainly
during the last decade. 
After centuries of the acceptance by our societies of the specialised knowledge required in the preparation of medications and a
clear separation of the responsibilities of the apothecary from the physician, this pattern was disrupted in the 20th century, when
an increasing number of pharmaceutical manufacturers entered in to “competition” with the primary role of the pharmacist as a
compounder of drugs. Although the procurement, storage, and dispensing of prescribed medications involve a significant societal
responsibility in terms of safety and efficacy of drug therapy, a conviction has developed within the pharmacy profession, that the
professional knowledge of pharmacists was not used to its full potential. Activities to assure the safe and appropriate use of drugs
became a new target leading to activities in the direction of more patient related aspects of drug therapy [2]. This perception was
present at about the same time on both sides of the Atlantic and most pertinently by hospital pharmacists and, mainly in the US,
also by pharmacists involved in education. It was logically named “Clinical Pharmacy”, meaning a pharmacy activity directed to
and in contact with the patient. 
The leaders of this new approach wanted to reinforce their message by founding professional organisations preoccupied with the
teaching and practical development of Clinical Pharmacy. In 1979 the birth of the American College of Clinical Pharmacy (ACCP)
and the European Society of Clinical Pharmacy (ESCP) took simultaneously place. The development of the discipline was impe-
tuous in the States and had an enormous impact on education, changing the image of the pharmacist very consistently in hospital
and later also in the ambulatory setting and in community. In commission of the ESCP a scenario analysis concerning the future of
the profession was elaborated which showed that the pharmacist, if he wants to keep a key role in our healthcare system, has to
move away from his clerk and controller role and assume an active responsibility as care manager [3]. This finding is important,
because in Europe - with the exception of the U.K. which for historical and linguistic reasons is stronger influenced by the US –
patient-oriented pharmacy was rather slow to develop and often limited to some visionaries. The main reasons considered for the
time lag in the development of the new role of the pharmacist in Europe are:
1) the historically warranted monopolistic position of the profession which was not contributing to stimulating the need for change;
2) the many educational systems and languages which separate the numerous European countries from each other;
3) the lethargy of teachers at our universities who lost contact with the new reality of the profession.
If on the academic level initiatives were hardly adopted to implement a new orientation of the profession, hospital pharmacists,
directly confronted with the negative impact of poor pharmaco-therapy on patient’s health and on costs, recognised first the
importance of adopting the concept of Clinical Pharmacy in practice. In the recent years there has therefore been a spread of acti-
vities which can be all integrated under the term “Clinical Pharmacy”: drug-information centres, drug formularies, elaboration of
therapeutic guidelines, pharmaco-epidemiology, pharmaco-economy, clinical nutrition, centralised cytostatic-preparation, intrave-
nous admixture programs, therapeutic drug monitoring, and of course, the presence of the pharmacist in the different depart-
ments and units of the hospital, providing clinical pharmacy services directly to the patient. 
“Clinical” is in many European languages almost synonymous to “hospital” and the first application of Clinical Pharmacy (in hospi-
tals) reinforced this message. To demonstrate that the new activities are not at all restricted to the hospital, the definition of the
goals of the  ESCP have been deliberately formulated as follows: “ Developing and promoting the rational and appropriate use of
medicines by the individual and by society” and there is since many years a strong conviction in the Society, that there is a need to
better integrate pharmacists working in community pharmacies and in ambulatory care and in primary care. Many professionals
working in these fields are frustrated about the professional perspectives, the gap between studies and practice and are conscious
about their changing societal role. The formulation of new opportunities and responsibilities under the denomination “phar-
maceutical care” [4] had therefore a world-wide echo and even so pharmaceutical care is an integrated part of the discipline
“Clinical Pharmacy”, the identification with the new expression was much easier for community pharmacists. The title of last years
ESCP Annual Symposium in Jerusalem was hence to stress the message that there is a scientific society which is actively involved in
promoting the idea of “pharmaceutical care” in Europe. The increasing professionalism of the International Secretariat of the
Society and the building up of a strong collaboration with the SIR (Stevenshof Institute for Research) in Leiden, a University bound
Institute with a postgraduate course in practice-oriented pharmaceutical research, shall maintain the pioneer role of the Society in
the development of a new professional image and stronger co-ordination in this field in Europe.  
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The pharmaceutical profession can play an important role in the changing healthcare systems as far as education and training are
adequately adjusted to prepare students for their future roles. The early integration of students as a “pressure group” is important
to change education. For the first time, a Student’s Symposium organised by the European Pharmacy Student Association (EPSA)
together with the ESCP will be held in 1999 prior to its Annual Symposium [5], The title “From Student to Clinical Pharmacist:
Bridging the Gap” can further contribute to change professional understanding in the upcoming generation. National and inter-
national societies can also make pressure to change the curriculum as to integrate a high level background in pharmacotherapeu-
tics, preparing the pharmacist for a greater involvement in the prescribing process, along with the basic underlying sciences which
are a condition for the development of pharmacy as a science oriented profession. It is important that more and more practitioners
are integrated in the teaching process at University level, to bring science and practice together for the best of the patient.
We should not see any antagonism between clinical pharmacy, hospital pharmacy, community pharmacy and pharmaceutical
care. The latter fits easily in the concept of Clinical Pharmacy which will have to integrate a growing part of the activities of com-
munity and hospital pharmacists. Clinical Pharmacy is therefore not limited to one of them but has an overlapping character which
can contribute to a better understanding between the different professional categories. Moreover it is an extremely helpful con-
cept to prepare pharmacists for an integrated healthcare system with minimal separation between hospital and ambulatory care.
References
1 Cairns C. The effect of patient-focused care on the activities of clinical pharmacists. 3rd Congress of the EAHP, Edingburgh 12-14 March 1998.
2 Zografi G. An essential societal role. The Annuals of Pharmacotherapy 1998; 32: 471-4. 
3 Leufkens H, Hekster Y, Hudson S. Scenario analysis of the future of clinical pharmacy. Pharmacy World and Science 1997; 19:182-5.
4 Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990; 47: 533-43.
5 1st EPSA / ESCP Student Symposium 13 October 1999 Berlin, prior to the 28th Annual Symposium of the ESCP.
G.L. Zelger  (Past President)
G.Scroccaro  (President)
Y.A. Hekster  (Vice President)
A. Floor-Schreudering  (Director of the ESCP)
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ESCP PRESS RELEASE
ESCP 28th European Symposium on Clinical Pharmacy
Bridging the Gaps – The Future of Clinical Pharmacy
14th –16th October 1999
Berlin, Germany
Although our goals are still the same, Clinical Pharmacy had and has to adapt to a changing world. One of the big challenges
in the future is to bridge gaps among different health care activities, professions and disciplines. Because of its
interdisciplinary orientation and its unique combination of scientific and practical activities Clinical Pharmacy is predestined
to do this job.
It is our pleasure to invite you together with the Federal Union of German Associations of Pharmacists (ABDA) and the
German Association of Hospital Pharmacists (ADKA) to the 28th European Symposium on Clinical Pharmacy with the main
theme “Bridging the Gaps – The Future of Clinical Pharmacy”, which will take place in Berlin, Germany, from 14th to 16th
October 1999.
The scientific programme will focus on interesting subjects for Clinical Pharmacists in community, hospital and academia,
where co-operation and joint efforts are most needed. As in previous years the Symposium is an excellent opportunity to
meet up with colleagues and to exchange ideas and experiences on all areas of Clinical Pharmacy.
The Symposium will be held close to the historic centre of the city where you can feel the spirit of different centuries and
observe the rise of a new European metropolis bridging Eastern and Western Europe.
We look forward to welcoming you to Berlin in October 1999!
Maria Rivera Giovanna Scroccaro
President of the Symposium President ESCP
ESCP Spring Conference on Clinical Pharmacy
Clinical Pharmacy Skills for the New Therapeutic Horizons
11th –13th May 2000
Reykjavik, Iceland
It is our pleasure to invite you together with the Pharmaceutical Society of Iceland to participate in the Spring Conference of
the ESCP which will be held in Reykjavik, 11th –13th May 2000. The theme of the Conference is Clinical Pharmacy Skills for
the New Therapeutic Horizons.
The scientific programme will appeal to clinical pharmacists both in the hospital and the community settings. In the plenary
sessions distinguished practitioners will address the question: What clinical skills does the pharmacist need as a clinical
practitioner, as a clinical scientist, as drug evaluator, and as an educator? In the workshops you will get an opportunity to
exchange ideas and experiences on research projects, patient monitoring and small group teaching to name a few of the
topics. Round table conferences, mini-symposia, short communications and poster sessions will add to the possibilities for
pharmacists from all over Europe to meet with colleagues and share views and experiences.
Reykjavik, the venue of the Conference, offers you the opportunity to enjoy the clean atmosphere of a city next door to
nature, the charm of the old small town mingled with the vivid development of a modern city. Reykjavik will be one of eight
European cultural cities in the year 2000 so a lot of cultural activities can be expected. Besides, 1000 years of Christianity in
Iceland will be commemorated this year as well. Not to forget the physical needs, being situated in a geothermal area,
Reykjavik offers you a considerable number of swimming pools where you can let the warmth of the natural hot water relax
your stressed muscles.
We look forward to welcoming you to Reykjavik in May 2000.
Kristján Linnet Giovanna Scroccaro
President of the Conference President ESCP
For more information on the above mentioned Conferences or on ESCP please contact ESCP International Secretariat, Theda Mansholtstraat 5b,
2331 JE Leiden      Tel: +31/71-5722430     Fax: +31/71-5722431     E-mail: secretariat@escp.nl.
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PLENARY LECTURES
1 WHAT IS THE RATIONALE FOR BASING DECISIONS ON
EVIDENCE?
A. Stevens  
If the rationale for basing decisions on evidence is itself self-evident, it is curious that it was not
always thus. Indeed the evidence based health care movement is something of a revolution. There is a
proliferation of journals dealing solely with the evidence base of health care. Conferences on the
subject are appearing at an unprecedented pace. And there is serious investment in strengthening the
evidence base of health care.
Academic efforts to furnish the evidence base of health care have long existed. The current
revolution has three distinct antecedents in: (1) cost-effective analyses produced by health
economists in a trickle from the mid 1970s to a torrent in the 1990s; (2) the evidence based medicine
movement itself with its roots in clinical settings as a way of defining and resolving clinical
problems; (3) health technology assessment initiatives — the earliest in the United States set up in
1972 — but in many other countries since — in which the focus is on the production of evidence with
both a clinical and policy relevance.
These three traditions have been brought together by the growing appetite for evidence based health
care. This appetite exists at a political public health and clinical level. It follows from three related
observations made in many countries on the rapid rise of the cost of health care — with new
technologies from a variety of innovations in genetics, biomaterials and IT for example; on
increasing anxieties about ineffective health care or its corollary of delayed effective health care; and
on the establishment of a cadre of health care management professionals whose job it is to be
responsible for cost-effectiveness monitoring — in the UK this was notably mediated by the
purchaser-provider split.
The response to these observations have been a multiplicity of initiatives designed to overcome (1)
the lack of availability of relevant high quality information e.g. through the Cochrane collaboration;
(2) access problems to relevant high quality information e.g. through a variety of evidence based
compendia; (3) inadequate skills in finding, appraising and acting on evidence e.g. through the
critical appraisal skills programme, and (4) barriers in the organisation of work or care such as
through the development of guidelines.
Clearly the underlying rationale for evidence based decision-making rests on anxieties about its
alternatives: anecdote experience and conventional wisdom-based decision-making. There is a
variety of evidence that the traditions of decision-making not using high quality evidence is flawed,
classically in the have of the immediate treatment of coronary artery disease, but in almost every
other area of health care delivery too.
However, the rationale for work for those in evidence based health care must also depend on how
successful it is in taking the place of alternative means of decision making. When innovations in
encouraging evidence-based decisions are themselves put to experimental test, the results are not
always encouraging although at a pan-clinical level. There is a growing sea change in the use of
evidence in health care.
United Kingdom 
2 HOW IS EVIDENCE IN HEALTH CARE EVALUATED?
Antonio Nicolucci
There is a general agreement that clinical decisions should be based on the best scientific evidence,
and the need for systematically finding, appraising, and using research findings as the basis for
clinical-problem solving (evidence based medicine, EBM) has been often underlined.
The synthesis of the available scientific evidence is obtained by systematic literature reviews, with
the aim of establishing the real yield of a medical procedure, the consistency of research findings and
their generalisability to different patient populations and settings. The use of explicit methods in the
identification, quality assessment and, where appropriate, quantitative combination of study results
(mesa-analysis), allows to limit bias and improve reliability and accuracy of conclusions.
While a great attention has been devoted to the development and standardisation of the procedures
underlying EBM and to the production of evidence-based clinical practice guidelines, it is still not
clear how we can assess whether medical decisions in the real world are evidence based.
The major limitation is indeed related to the discrepancy between the narrow focus of research
results, addressing specific questions, and the complexity of most clinical problems. Furthermore,
evidence from randomised controlled trials mainly refers to pharmacological interventions, and
many areas of uncertainty still remain for other aspects of clinical practice (prevention, diagnosis,
rehabilitation).
It has also been emphasised that a truly evidence-based medicine does not consist in the mere
application of trials results in routine practice, but must incorporate patient preferences and priorities
in the decision process.
In the presentation, possible solutions to overcome the dichotomy ‘evidence based yes/not’ will be
proposed by including some measures of the multifaceted doctor-patient interactions.
Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, 66030 S.
Maria Imbaro (Ch), Italy
3 HOW IS EVIDENCE IMPLEMENTED IN THE USE OF
MEDICINES?
J. Bonal 
During the last decades, clinical pharmacy has been developed in many hospitals in Europe,
sometimes with conflicts related to professional competition with other members of the health care
team. Legislation in different countries has stated the need to implement clinical pharmacy practice
in hospitals as well as in community setting. WHO recommendations (1) are also underlying clinical
pharmacy as a one of the essential activities required for European health systems.
Efficient drug prescription and use is a permanent challenge in health care. Cost/Effective decision
making presents many difficulties and limitations, most of them related to the lack of relevant
information for a particular health care environment, specially for the effectivity understood as the
effect of the therapy out of the frame of randomised clinical trials (RCT). However, when there is
evidence, problems are related to a scarce use of it in the decision making process (2). The effectivity
of a drug depends on several factors related to the health context, particularly appropriate indication,
clinical characteristics of the patient or comorbidities, dose prescribed, compliance of the patient and
therapeutic monitoring level.
Research on efficacy and effectivity are frequently based on intermediate indicators instead of final
endpoints. This fact is adding confusion on prescribing decision making.
Although poorly validated biological indicators are frequently used as outcomes, they are not useful
as final health outcomes (3).
Walker (4), talking about relevance of outcome measures in pharmaceutical care outcomes, stated
that desired outcomes can be expressed by the following equation:
Pharmaceutical care outcomes = Pharmacoterapy outcomes + Pharmacy service outcome
This means that to achieve an efficient pharmaceutical care we need not only evidence of
pharmacotherapy but also evidence on the effectiveness of pharmacy services we are providing. If
evidence on drug prescribing is not easy to obtain and when exist it is not frequently used, evidence
on pharmacy service outcomes is even less frequent and there are very few articles showing such
evidence as has been pointed by Hekster (5).
Some studies evaluating clinical and pharmaceutical care outcomes will be presented, emphasising
those based on solid endpoints demonstrates how clinical pharmacist intervention is improving
patient health in terms of cure of the disease, prevention of toxicity and side effects, morbimortality,
patient satisfaction and value for money.
Health politics in Europe and inter-professional competition, will drive Pharmacy to a higher degree
of specialisation and to document better outcome evaluations in order to offer evidence of the
efficacy of clinical pharmacy practice in terms of health care outcomes, as well as evidence on the
value for money of such pharmaceutical service.
References:
1. WHO; The role and functions of the community and hospital pharmacist in the health care
systems of Europe, Lunde I., Dukes G. Editors. 1989, STYX publications. Postbus 1344,
Groningen, The Netherlands.
2. Granados A, Jonsson E, Banta HD et al. EUR-ASSESS project subgroup report on
dissemination and impact. Int J Technol Asses Health Care 1997; 13:220-86
3. Pons JMV, Marcadors o resultats intermedis en la mesura de l’efecte de les intervencions
mediques. Informatiu AATM 1997;11:11-12
4. Walker R, Outcome measures in patient care pharmaceutical care vs. Pharmaceutical public
health. Progress in Clinical Pharmacy: Optimising pharmacotherapy process, Luscombe DK,
Husson MC, Caramona M, editors 1997, ESCP publ. Pp 56-59
5. Hekster YA, Pharmacoepidemiology. Scroccaro G, Martini N, Delporte JP, MC, Walker R,
editors 1195, ESCP publ. pp. 169-170
Barcelona, Spain
4 EVALUATION OF CLINICALAND ECONOMIC OUTCOMES: A
CASE STUDY WITH HEPATITIS B VACCINES
T. Jefferson
The notable increase in quantity of economic evaluations in the last two decades has not been
matched by good methodological standards. This problem has present in the field of economic
evaluations of Hepatitis B vaccines, universally used to justify decisions to vaccinate whole
populations. Traditionally single studies have been evaluated with little regard to a population of
similar studies. However, serious methodological problems are highlighted when a population
approach (systematically conducted reviews) is applied to the topic. The results of two systematic
reviews conducted by in1993 and 1996 showed three problem areas. A sizeable minority of reports of
economic evaluations of HB vaccines are unclear as to the study question, showing a basic ignorance
of the first rule of conducting scientific research. Secondly, the basic epidemiological assumptions
upon which the economic models are based showed variability that persisted even after stratification.
This finding raises the question of the accuracy of the epidemiological knowledge base of hepatitis B
and its progression. Lastly, a further minority of studies show weaknesses in the basic methods of
conducting and reporting economic evaluations. Examination of these problem areas leads to the
conclusion that no assessment of the efficiency of hepatitis B vaccines can be drawn from the
evidence. Addressing the problem of poor methodological standards concerns the whole research
community but, as a proportion of economic evaluations are published, one obvious mean of exerting
pressure to increase and maintain methodological standards is the editorial and peer review process.
Readers of economic evaluation literature should beware of uncritical acceptance of study
conclusions without appraisal of the methods used in the study.
Edmund Parkes Professor of Preventive Medicine, Cochrane Vaccines Field, Army Medical
Directorate, Ministry of Defence, Keogh barracks, Ash Vale, Hants GU12 5RR, E-mail:
zorria@epinet.co.uk. 
abstracts 1 99  09-06-1999 15:18  Pagina A5
Pharmacy World & Science
Volume 21 Nr. 1A 1999
A6
5 PHARMACEUTICAL CARE IN PSYCHIATRIC DISEASE
A. Dorevitch
Psychiatric pharmacy services in Israel include clinical, teaching and research activities. A
psychiatric clinical pharmacist monitored medication response over a 10-year period for chronic
schizophrenic outpatients. Successful treatment resulted in a decreased rate of re-hospitalisation,
shorter length of hospital stay and decreased total neuroleptic dosage as compared to the 10-year
period prior to entry into the study. Another study in the inpatient psychiatric facility describes 109
physician-initiated consultations that were directed to the clinical pharmacist. Of the 229
recommendations made by the psychiatric pharmacist 103 (88.2%) were accepted. Major question
types included: side-effects, non-response, preventive measures and mixed factors. Sixty-seven
percent of patients exhibited a very satisfactory or satisfactory response as measured by global
effectiveness of pharmacist interventions. Psychiatric clinical pharmacy services though cost-
effective and available in Israel have yet to be sufficiently expanded to meet current needs.
Clinical Senior Lecturer, Hebrew University Faculty of Medicine, and Talbieh Mental Health Center,
18 Disraeli St., Jerusalem, Israel
6 EVIDENCE-BASED PHARMACEUTICAL CARE IN EPILEPSY
M. Bialer
Epilepsy is a common and chronic disease which affects 1 % of the global population. At present
there are four major (established) antiepilepltic drugs (AEDs): phenobarbital, phenytoin,
carbamazepine and valproic acid. About 25% of epileptic patients do not respond to these major
AEDs, and their therapy is associated with side effects including teratogenicity and hepatotoxicity
and pharmacokinetic drug interactions. In the last decade a numbers of new AEDs have been
approved across the world. These new AEDs are: gabapentin, lamotrigine, oxcarbazepine, tiagabine,
topiramate, vigabatrin and zonisamide. The advent of the new AEDs brought a welcome expansion to
the pharmaceutical care and pharmacological armamentarium against epilepsy. However it also made
therapeutic decisions more complicated because physicians and clinical pharmacists are now
confronted with an array of about 15 different AEDs, whose relative merits have not been fully
characterised. A clinical choice of AED should be based firm evidence generated in randomised
clinical trials, in which drugs efficacy and tolerability are investigated.
In the current presentation assessment of the pharmacodynamics (PD) and pharmacokinetics (PK) of
the new AEDs in patients with refractory (therapy resistant) epilepsy will be assessed. The major PD
criterion for outcome assessment or evidence-based pharmaceutical care in epilepsy is seizure
counts. There is a clear evidence that each of the above new AEDs is better than placebo at
preventing seizures. The analysis of the new AEDs is based on the percent of refractory patients who
have a more than 50% reduction in their seizure frequency. In addition, reported side effects and
percent withdrawal from clinical trials also have to be included. This comparative PD-PK analysis is
done in order to characterise the current status of evidence-based pharmaceutical care in epilepsy.
Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of
Jerusalem, POB 12056, Jerusalem 91120, Israel.
FREE COMMUNICATIONS
1 EVIDENCE-BASED PHARMACEUTICAL CARE: WHICH
EVIDENCE FROM LITERATURE?
M. Romereo, G. Di Sabatino, F. Ravaioli, C. Spoltore, C.N. Venanzi
Background: Evidence-based concept is a new emerging paradigm for medical and pharmaceutical
practice. It de-emphasises intuition, unsystematic clinical experience, and pathophysiologic rationale
as sufficient grounds for clinical decision making and stresses the examination of evidence from
clinical research.
Aims: To know how the evidence based concept fit in with the normal activities of clinical pharmacy
and to review the contributions of clinical pharmacy to delivery an evidence-based pharmaceutical
care.
Methods: A medline review of the literature from January 1995 through April 1998 was conducted.
Various research’s strategies were carried out through different keywords combinations, such as
‘evidence-based pharmaceutical care’, ‘evidence-based healthcare’, ‘evidence-based medicine’ and
‘clinical pharmacy’, ‘evidence-based approach’ and ‘clinical pharmacy’ or ‘ pharmaceutical care’.
Results: The combination of key words has turned out to be unsuccessful. On the contrary, a total of
126 citations were identified using ‘pharmaceutical care’ alone. The main results of our research can
be summarised in three points:
1. Few research studies (18%) have evaluated the provision of pharmaceutical care in a defined
population or disease or setting: elderly patients (3 studies); chronic illness (2 studies); diabetes,
asthma, HIV (2 studies each); cancer (1 study); acute care setting, outpatient dialysis setting (1
study each), etc.
2. A substantial number of studies (50%) discussed the pharmacist’s functions and responsibilities
in providing pharmaceutical care. In particular, the following aspects have been considered
fundamental: measuring therapeutic outcome; establishing a pharmaceutical care database;
developing models of pharmaceutical care for educating students; establishing patient-
pharmacist relationships and implementing collaboration with physicians based upon consensus
guideline.
3. The practise of evidence based pharmaceutical care seems to be still unusual. No article
discussed about the evidence-based concept. The aforementioned studies, however, did not
follow the evidence-based approach in asking for considerable clinical questions, finding and
appraising relevant data, and harnessing that information for everyday clinical practice.
Conclusion: Evidence based medicine requires new skills of the health care providers, including
efficient literature searching and application of formal rules of evidence evaluating the clinical
literature. Professional associations have an important role to play in ensuring that research-based
information is included in educational activities and clinical as well as pharmaceutical guidelines.
Centro Studi SIFO, Consorzio Mario Negri Sud, Santa Maria Imbaro (Chieti), Italy
2 EFFECTS OF TWO INTERVENTIONS ON THE
PHARMACOTHERAPY DURING AND AFTER HOSPITAL STAY
IN PATIENTS ADMITTED TO GENERAL MEDICAL WARDS
H.S. Lau, M. Klerkx, A.J. Porsius, A. de Boer
As avoidable iatrogenic illness is common, there is great need for interventions that improve
appropriate drug prescribing. We studied the effects of two interventions, one based on providing
additional information from the community pharmacy on the medication used before hospital
admission (intervention A) and one based on that same information supplemented with a detailed
report on drug-related problems set up by on expert panel (intervention B), on the pharmacotherapy
during hospital stay and at hospital discharge, and length of hospital stay of patients admitted to
general medical wards.
Patients admitted to the general ward of 2 acute care hospitals were included in the study. In one
hospital patients were randomised over an intervention group who received intervention A (n=75),
and a control group (n=77). In the other hospital, patients were randomised over an intervention
group who received intervention B (n=55), and a control group (n=52). The length of admission in
the control group, the intervention group A, and the intervention group B were 16.5 (14.4-18.6), 12.6
(10.2-15.0) and 15.3 (11.9-18.8) days, respectively. The number of drugs during admission were 7.5
(6.7-8.2), 7.1 (6.0-8.2), and 8.6 (7.1-10), in the 3 groups, respectively. Results for the number of
drugs at discharge were 4.6 (4.1-5.1), 4.4 (3.7-5.2), and 4.9(3.8-5.9), for the number contraindicated
drugs in discharge medications 0.45 (0.27-0.63), 0.26(0.10-0.43), and 0.46(0.19-0.74), for the
number of drug interactions in discharge medication 0.48(0.30-0.65), 0.47 (0.25-0.69), and 0.73
(0.28-1.2), and for the reduction in the number of drug related problems as evaluated by an expert
panel 35%, 25% and 23% in the 3 groups, respectively. The differences between the intervention
groups and control group were not statistically significant, except for the length of admission
between intervention A and the control group. Regardless of intervention or control group, the
proportion of drugs that was not continued during admission was increased for those drugs that were
not registered in the medical records (40-61%) in comparison with drugs that were registered (13-
20%).
We conclude that interventions that are solely based on written recommendations to improve
appropriateness of medication prescribing in patients admitted to general medical wards have no
effect on the number of drugs prescribed during hospital stay, the number of drugs, the number of
contraindicated drugs or the number of drug interactions at discharge, the length of hospital stay, or
the number of drug related problems as evaluated by an expert panel. Failure of registration in the
hospital medical records of drug use before admission may be associated with unintentional
discontinuation of drug therapy during admission.
Department of Pharmacoepidemiology & Pharmacotherapy, Faculty of Pharmacy, Utrecht
University, Utrecht, The Netherlands
3 EVALUATION OF DRUG MONITORING PRACTICES: EFFECTS
OFAN EDUCATIONAL CAMPAIGN
E.R. Smith*, A.C. Greenberg, A. Yinnon**
Following the introduction of once-daily aminoglycoside dosing, the clinical pharmacists noticed
that some confusion existed in the correct manner of monitoring blood levels for these drugs as well
as for the other commonly monitored antimicrobial, vancomycin. An audit was carried out to
determine what the problems were and their extent, and to try and improve the process of blood level
monitoring of antibiotics through an educational effort directed at the medical staff by the clinical
pharmacists of the hospital. The study consisted of two stages interspersed with an educational
campaign. Patients eligible for the study were those receiving either gentamicin, amikacin or
vancomycin or any aminoglycoside and vancomycin. Patients included all adults, children and
neonates who had been receiving therapy with these drugs for at least 48 hours during the study
periods. The three steps of drug level monitoring were assessed -1. Reason for ordering 2. Accuracy
of blood level taking and 3. The doctor’s response to the results of the blood levels. Between the two
stages an educational effort was made to increase the medical staff’s awareness and knowledge of
antibiotic level taking. During this stage a new form for antibiotic drug level requests was introduced.
The new form allowed the clinical pharmacist’s recommended changes to be documented on the
form. The second stage of the study took place after the education campaign and was used to assess
whether there had been an improvement in staff competence in the correct manner of ordering, taking
and interpretation of serum drug levels after the educational effort. In the first stage of the study 161
patients were entered and in the second stage 198 patients. The results for step one, the reason for
ordering showed a small increase in the number of justified requests between the two stages in the
medical (70.2% in stage 1 to 72.7% in stage 2) and surgical departments (70.4% justified in stage 1 to
72.9% in stage 2). However the intensive care departments showed a significant decrease in the
number of justified requests (65.7% is stage 1 to 42.9% is stage 2). p<0.005. For step two -
assessment of serum level taking- a small but statistically insignificant improvement in the serum
level taking for each of the three drugs is seen between the two stages. When the results were pooled
and compared for appropriateness of serum level taking there was also an improvement in all three
categories of departments. These results however, did not reach statistical significance. A significant
(p< 0.001) improvement in the correct interpretation of the serum drug results (step three) was shown
between stage one and stage two. When the departments were pooled, improvements in the
interpretation of results for all departments groups are seen, but it is only the medical departments
that show a statistically significant (p<0.025) improvement. When the clinical pharmacist had direct
input into the therapeutic drug monitoring process, such as in giving advice on the interpretations of
the serum blood level results, then it was seen that a significant improvement ( p< 0.025) occurred
between stage one, when there was no clinical pharmacy involvement and stage two when the
clinical pharmacist’s recommendations regarding dosage and dosage interval were recorded on the
request form that was subsequently returned to the departments. In the other two steps of the drug
monitoring process, where there was no direct input of the clinical pharmacist, the results showed no
significant improvement between the two stages of the study. The study shows that a clinical
pharmacist can exert a significant effect on the monitoring of serum drug levels.
* Department of Pharmacy, Shaare Zedek Medical Center, Jerusalem. Israel 
** Department of Infectious Diseases, Shaare Zedek Medical Center, Jerusalem, Israel
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4 THE DRUG INFORMATION CENTRE AND ITS SUPPORT TO
THERAPEUTIC COMMITTEE
T. Cassani, D. Guzzo, G. Scroccaro
Introduction: The Drug Information Centre (DIC) is located at the Pharmacy of University
Hospital of Verona Hospital Firm (two hospitals for a total of 2.300 beds). Among other
activities, DIC co-operates with the Therapeutic Committee (P&T), established in 1977 to
promote a rational use of drugs within the hospital.
Objectives and methods: The aim of this study is to describe the support provided by DIC of
P&T, through the analysis of the work done from 1995 to 1998.
Results: During the years 1995-1998, 16 meetings at P&T were organised as well as 6
meetings of panels of experts constituted by P&T in order to define Guidelines for the correct
use of drugs and to carry out periodic revisions of the Hospital Formulary (HF).
On this purpose DIC has prepared, through the evaluation of the literature derived from
bibliographical research, 107 dossiers of drugs, 6 dossiers of comprehensive review for
specific problems, 13 analysis of the consumption of largely used single drugs and drugs
categories.
The material arranged by DIC has allowed the P&T to take the following decisions: 74
inclusions in HF on free distribution, 34 inclusions in HF on justified request, 28 non
inclusions in HF, 76 exclusions from HF, 16 suspended judgements waiting to acquire further
elements of evaluation, 30 modifications of previously taken decisions, 27 confirmations of
previous decisions.
Thanks to the co-operation between DIC, P&T and panels of experts, 4 HF reviews were
made and 4 Guide-Lines were defined for appropriate use of specific drugs or drugs
categories (antibiotic profilaxis in surgery, gabexate mesilate, octreotide and somatostatine in
pancreatic disease, intravenous immunoglobulins, new lipidic formulations of amphotericin
B).
In order to, disseminate the decisions of P&T, DIC has prepared 10 Bulletins (from October
1997 also available in Internet http://www.sfm.univr.it/Farmacia/sdf-txt.htm) and 15
informative sheets.
Furthermore, through the analysis of drug consumption and justified requests prepared by
DIC, P&T has been able to verify the validity of the measures taken.
Conclusions: The analysis of the activity of P&T during the years 1995-1998 points out that
support provided by DIC to P&T is of essential importance and it consists of: 1. Reviews of
literature on drugs; 2. Co-operation with panel of experts in order to define Guidelines or HF
revisions; 3. Analysis of drug consumption and justified requests to verify possible
intervention areas and the impact of P&T decisions on medical practice; 4. Dissemination of
P&T decisions within the hospital.
Department of Pharmacy - Azienda Ospedaliera ‘lstituti Ospitalieri di Verona’ – Italy
5 THE CENTRE FOR DRUG DOCUMENTATION: FROM THE
HOSPITAL TO THE COMMUNITY
G. Dusi*, L. Bragantini*, G. Scroccaro*
Introduction: The Centre for Drug Documentation and Information (CIF) was established with a
regional deliberation in 1975. While proceeding through a progressive change that led it to qualify its
role as an active knowledge ‘promoter’ rather than a passive information ‘transcriber’; CIF has
become today a steady landmark for informative activity aiming at a rational use of drugs.
Purpose and methods: CIF activity in the years 1996-1997 has been examined by dividing answers
into queries from inside and queries from outside.
As far as requests from inside are concerned we have focused on those regarding substitution of an
ongoing therapy during patient hospitalisation with drugs included in the Official Hospital Formulary
(PTO).
Results: During the years 1996 –1997, 418 (24.8%) requests from outside and 1270 (75.2%) requests
from inside occurred.
By examining requests from outside in the same period we have observed that most of queries were
concerned with side effects (12%) followed by those regarding speciality synonyms of the same
active principle (9%) and by literature references (8%).
In particular the main users outside the hospital structure have revealed community pharmacists
(16.5%) and citizens (16.0%)
Request from inside on behalf of physicians aiming at replacing patience ongoing therapy with
branded pharmaceuticals from the Formulary represent 9% of the whole 1270 requests from inside.
Cardiovascular drugs (54%) represent the main therapeutic category for which a substitution is
requested. This fact can be partly explained if we consider that there are about 196 commercially
available active principles (including associations), while those included in PTO are 48 (24.5%).
Antibiotics are just following this category (4.5%).
In this latter case there are 107 commercially available active principles (and associations) of which
44 (41.1%) included in PTO.
Conclusions: The analysis performed in these years of activity has shown the importance for a
Centre for Drug Documentation being open even to queries coming from outside or to those
regarding therapeutics already working during hospitalisation. In order to allow and increase better
relationships with general medicine physicians and patients a toll free phone number called ‘green
number’ was created in May 1998.
* Center for Drug Documentation and Information, Verona Hospital, Italy
6 DRUG INFORMATION WEB PAGES: AN UPDATE
Venturelli A,. De Marino C., Zeuli L., *De Rosa M., *Rinieri E., **Giuliani G., Cozzolino S.
Introduction: In 1996 the Italian Society of Hospital Pharmacists planned the creation of a web site
‘Eupharma’ at the URL http://www.sifo.it.
The site is organised in many sections regarding the different Hospital Pharmacists fields.
The Biomedical Documentation Center of the Cardarelli Hospital of Naples carried out the task of
realising the web pages related to drug information.
These pages are divided in two different sections:
- a consultive section;
- an interactive section.
The growing number of users of the Sifonetwork in Eupharma and the necessity to satisfy the mutable
requirements of the Hospital Pharmacists induced a continous extension and updating work of the
WebPages.
So in 1998 a project was elaborated to activate new sections in the web pages of drug documentation.
Aims:
- to create a network between the Italian Drug Information Centers;
- to create a frequent asked questions (FAQ) page: each Center will put in this page the most
interesting questions about drug information;
- to promote an active participation of the Italian Drug Information Centers to on-line projects;
- to allow the use of the on-line Sifo software BBS and Start;
- to provide the Pharmacists with detailed information about all public competitions published on
Italian Official Gazette;
- to permit the free use of Martindale;
- to provide the users with a temporary access to the OVID System to show its potentialities
- to create a page in which the people will put in their questions about Health World and where they
will find the solution of the drug related problems.
Methods: The project is in progress but some of the aims was already realised; in fact, thanks to the
collaboration of CINECA the web page about the public competitions is biweekly update. The page
for the people is under construction.
Regarding the free use of Martindale and the temporary access to the OVID System, the Eupharma
working group is negotiating respectively with the Medical Economics Italia srl and the Dea
International Library to provide the Pharmacists with these services.
Conclusions: The activation of these new sections could promote a greater interest from the Hospital
Pharmacists, other health professionals and the people in the Eupharma site.
Eupharma could be the tool:
- to improve the Hospital and Territorial Services efficiency;
- to increase the diffusion of the information and the integration of the experiences;
- to manage the problems about the Hospital Pharmacist Work.
Biomedical Documentation Center, Biofarmacological Sector, Cardarelli Hospital, Via s: giacomo dei
Capri no 66, 80131 Naples, Italy.
* Consorzio Interuniversitario Cineca, Bologna
** Servizio Aziende USSL 13, Treviglio
7 AN INFORMATIVE REPORT ABOUT FULL-TEXT RETRIEVAL
IN ITALY
De Marino C.,Venturelli A.,Mancini A., Scala D.,Cozzolino S., Zeuli L., *Albano M.
Introduction: In the last years the problem of bibliographic update in the pharmaceutical and
biomedical fields has been partly solved thanks to the creation of specific scientific databases; in fact
it is now possible to carry out researches on all over the world bibliographic reviews.
The most part of on-line or on CD-ROM bibliographic databases provide the users with the
references and often with the abstract. The careful reading of the abstract allows a critical selection of
the articles and the screening of the topics for the professional update.
However, for health professionals working in biomedical and pharmaceutical researches, it is often
necessary to consult the full-texts or the articles.
In Italy, the full-text retrieval is often a problem so the Biomedical Documentation Center of Naples
is carrying out a research to provide the Hospital Pharmacists and the other health professionals with
a general picture of the situation about document delivery.
Aim: To organise an informative report about full-text retrieval in Italy.
Methods: The preliminary phase dealt with the selection of the information about the document
retrieval tools. Therefore, first a bibliographic research in Medline database then an Internet research
by making use of the main search engines were carried out using the keywords ‘full text’ and
‘document delivery’.
In the executive phase, the most specific bibliographic references and the most interesting web sites
was selected and then organised in a report that will provide the health operators the following
information:
• the most important on-line and CD ROM full-text databases;
• the online full-text journals;
• the main Clearing Houses: document ordering, wait and payment;
• the Italian document delivery services;
• the better, the cheapest and the most reliable way to obtain a full-text.
Conclusions: 
In Italy, the lack of structured information from public or independent sources make health
professionals’ biomedical documentation approach difficult. To facilitate the approach to information
sources and to support health operators in their work it is necessary to improve the diffusion an a
national scale of the informative report about full-text retrieval in Italy; it may be inserted in the
Italian Society of Hospital Pharmacists web site (Eupharma) and/or published on Italian Scientific
journals.
Biomedical Documentation Center, Cardarelli Hospital, Via S. Giacomo dei Capri no 66, 80131
Naples, Italy
* Doctorline Viale Certosa 148 Milan, Italy
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8 QUALITY OF NUTRITION IN PATIENTS AT AN INTENSIVE
CARE UNIT
M.M.P.M. Jansen*, F. Heymer**, J.A. Leusink**, A. de Boer*
Adequate nutrition of patients remaining at intensive care units (ICU) is of great important since both
over- and undernutrition can lead to serious morbidity and even mortality. The aim of our study was
to examine whether patients at an ICU are adequately fed. A prospective follow-up was performed in
39 postoperative and non-surgical patients whom were on artificial ventilation and were at least two-
day on the ICU prior to inclusion. These patients were on average 65 years old (range 23 to 88) and
40% was female. For each patient the following data were collected. First, the exact amounts of
energy and macronutrients (carbohydrates, fat and proteins) given over 24 hours by parenteral and/or
enteral route were calculated (‘administered’). Second, on the same day indirect calorimetric
measurement (DeltratrecTM II metabolic monitor) was performed over 18 hours and urinary
nitrogen loss was measured over 24 hours in order to estimate energy expenditure and macronutrient
usage (‘measured’). Third, by means of the formula of Harris Benedict we calculated the needs for
energy and macronutrients based on the clinical information obtained on the day prior to the day the
indirect calorimetric measurements were performed (‘calculated’). For each patient the difference
between the amounts of energy, carbohydrates, fat and proteins administered, calculated and
measured were calculated. Furthermore, correlation coefficients between energy amounts
administered, calculated and measured were calculated.
In 30 patients (77%) the administered amount of energy exceeded the measured amount by on
average 671 kcal/24h and a maximum of 2166 kcal/24h. Nine patients received insufficient amounts
of energy (average 358 kcal/24h and a maximum of 1113 kcal/24h). Sixteen patients had a negative
protein balance (on average 33 g of proteins shortage per 24h and maximum of 93 g/24h).
Furthermore 25 patients were administered more fats and carbohydrates than were actually needed
(on average 73 g and 125 g per 24h, respectively). Coefficients of correlation between measured
versus administered, calculated versus administered and measured versus calculated amounts of
energy were 0.19 (p=0.25), 0.03 (p=0.87) and 0.57 (p=0.002), respectively.
In conclusion, a substantial part of patients at an intensive care unit are not adequately fed.
Improvement of the quality of feeding can be established by using the Harris-Benedict formula in the
prescribing of nutrition.
* Department of Pharmacoepidemiology & Pharmacotherapy, Faculty of Pharmacy, Utrecht
University, Utrecht
** Intensive Care Unit, St Antonius Hospital, Nieuwegein, The Netherlands
9 NUTRITIONAL SUPPORT IN CANCER PATIENT: AN
EPIDEMIOLOGICAL STUDY IN THE LOCAL HEALTH UNIT OF
ROVIGO – ITALY
R. Joppi*, C. Battistutta*, L. Monesi*, A. Ferraresc**, S. Toso**, E. Ferrazzi**
Introduction: In the last five years, guidelines have been developed for the use of nutritional support
at national as well as at international level. These guidelines intend to promote an ‘evidence based’ and
effective use of artificial nutrition in specific diseases and/or conditions.
With regard to cancer patients the artificial nutritional is part of the supportive therapies and its aim
(according to the American Society for Parenteral and Enteral Nutrition Guidelines) is to improve:
• the tumor response to anticancer therapy;
• the patient’s tolerance towards the therapy;
• the patient’s survival.
More and more frequently cancer patients are discharged on artificial nutrition. An European survey
shows that Italy was only second to France in the number of outpatients on nutritional support. Home
care for these patients strongly highlights the following problems:
1. the rational use of nutritional support;
2. the risk of complications;
3. the need for a specific training for specialists, relatives and caregivers involved in the
management of outpatients.
Objectives: The purpose of this study was to evaluate the impact of nutritional support guidelines on
the management of cancer patients; the role of the artificial nutrition in a global supportive care, the
quality of training and information for the outpatients, their relatives and other caregivers.
Methods: Using two different questionnaires and the ‘index day’ methodology, data from in- and
outpatients were collected. The questions focused on characteristics of the patient, type of tumor, kind
of nutritional support, management of cancer related symptoms and information for outpatients and
their relatives.
The data were processed according to the epidemiological computer program EPI INFO (version
6.04).
Results: In this study (one day survey) 55 adult patients (49 followed by the Oncology Unit and 6 by
the Home Care Service, respectively) were recruited. Out of the 55 patients 22 were male and 33
female, the mean age was 62,9 (range 31 – 97); SD 12,86), 3 were terminal cases, 7 received
nutritional support (2 were on Total Parenteral Nutrition and 5 on Enteral Nutrition). In the opinion of
physicians and nurses the cancer related symptoms were well controlled in the outpatients while in one
inpatient the management was estimated less than satisfactory. The outpatients were visited weekly by
the physician and twice a week by the nurse. No training or information was provided to the
outpatients and their relatives.
Discussion and conclusion:
1. the terminal cases did not receive TPN according to the guidelines;
2. the artificial nutrition was included in a global supportive care;
3. training or information for outpatients and their relatives or other caregivers were lacking.
These results pointed out that multicenter and collaborative epidemiological studies are needed to
gather information about and improve the use of nutritional support in these patients.
Servizio di Farmacia Ospedaliera – Ospedale Civile Viale Tre Martiri – 45100 Rovigo, Italy
* Hospital Pharmacy  ** Oncology Unit
10 PHARMACEUTICAL MANAGEMENT OF CLINICAL TRIALS
SPONSORED BY PUBLIC ASSISTANCE OF PARIS HOSPITALS:
THE INVOLVEMENT OF CENTRAL HOSPITAL PHARMACY
A. Tibi, B. Lehmann, F. Courteille-Laurencon, D. Pradeau
Public Assistance of Paris Hospitals (PA-PH) is the major French institutional sponsor of clinical
trials. Pharmaceutical quality of the investigational medicinal products is of particular importance for
non-industrial sponsors. In fact, various products are concerned (experimental products, non-
pharmaceutical starting materials…).
Moreover, all clinical trials in France are submitted to declaration to French Drug Agency, but not to
IND.
In this context, the Central Hospital Pharmacy (C.H.P.) has created a Clinical Trial Unit for the
pharmaceutical management of therapeutic trials sponsored by PA-PH.
This unit is in charge of the pharmaceutical analysis of the study protocols and of drug supply
(manufacturing, quality control, industrial contracts…). This also includes, for numerous
multicentric trials, the packaging and labelling of patients treatment, their shipping, the returns and
destruction with respect to good manufacturing practices. This unit has the support of several
partners within PA-PH (Analysis Laboratory, Manufacturing unit, Quality Assurance Department of
C.H.P., hospital pharmacists…) and the help of pharmaceutical companies for the supply of
investigational or comparator products (placebo, marketed product…).
Up to date, Central Hospital Pharmacy works on more than 100 different clinical trials and offers a
reliable structure for the management of pharmaceutical requirements of institutional clinical trials.
Central Hospital Pharmacy, Public Assistance of Paris Hospitals, 7 rue du Fer a Moulin 75005 Paris,
France
11 CLINICAL TRIALS IN HYPERTENSIVE AND HYPERLIPEMIC
DISEASES: REVIEW OF THE ACTIVITY OFAN ETHICAL
COMMITTEE
M.P. Alberti, V. Berto, G. Scroccaro
Cardiovascular diseases are the first cause of death in the modern developed society. High blood
pressure and hyperlipemia have been shown to be important risk factors for these diseases. Treating
such conditions should so lower these events: that’s why the clinical trials for antihypertensive and
hypolipemic drugs are of great interest for the scientific community.
Aims: Goals of this study were: a) to evaluate the characteristics of trials involving drugs belonging
to the hypertensive and hypolipemic agents, according to their design and their objectives; b) to
examine the EC’s opinions; c) to monitor the development and results of approved studies.
Methods: All of the trials submitted to the EC of Verona since 1992 until now were revised, and
those related to antihypertensive and serum lipid reducing agents were set apart. These trials were
then examined according to their design, their objectives, and the EC’s opinions. Final reports sent to
the Committee by investigators and sponsors were also examined and, when they were lacking,
requests were sent to complete data.
Results: 45 out of 489 (9%) examined by the EC between April 1992 and May 1998 were related to
this kinds of diseases. These trials were connected to 39 different protocols. Drugs investigated were
mostly calcium channel blockers (14 protocols), angiotensin II antagonists and ACE inhibitors plain
or in combinations (8 protocols each). Diseases studied included 19 times primary hypertension, 13
times hypertension in combination with different diseases (i.e.: nefropathy, diabetes mellitus,
cardiopathy), 7 times troubles in lipid metabolism. The analysis of protocols design showed that 36
were controlled and 3 uncontrolled; 4 trials were monocentric and the other 35 multicentric. Only
two out of 39 protocols were spontaneous, while the others had a sponsor. 5 studies had less than 50
patients planned, 3 between 50 and 100, 9 between 100 and 200, 14 between 200 and 500, 3 between
500 and 1000, and 5 more than 1000 (range 10 – 18.000). A particular attention was paid to the goals
of trials: they were four times the evaluation of effects on mortality and cardiovascular morbidity, 9
times the effect on target organs and 26 times the evaluation of blood pressure reduction or
tolerability of drugs on a short perspective, thus showing a persistent tendency to evaluate surrogate
endpoints rather than hard ones. Two trials belonged to phase II, 28 to phase III and 9 to phase IV: for
the most part they planned to evaluate new chemical entities (NCEs). More than half of these trials
(21) were approved by the EC, 16 were approved after amendment and two were suspended waiting
for amendments. 32 protocols were approved until the end of 1996: according to investigators
reports, 15 of them were finished, 6 were ongoing and one could not start; for 10 of them
investigators gave no information. Only 12 reports were sent by sponsor: 2 reported an ‘in house’
report, 6 said that results were in printing; 3 protocols had a publication of results, and only one was
published and presented at a conference.
Conclusions: The analysis of trials in the area of hypertension and hyperlipemia submitted to the EC
of Verona Hospitals shows that assessment of efficacy is still focused on surrogate end points and
NCEs, that don’t always mean innovate drugs, rather than on hard end points for the existing drugs.
However trials design is almost always in formal agreement with the CPMP’ guidelines. On a single
centre level more than half of the trials have been finished while multicentric results are often
lacking. This enforces the role of EC as monitor of diffusion of results.
Department of Pharmacy - Ethical Committee’s Secretariat - Azienda Ospedaliera ‘Istitutiti
Ospitalieri di Verona’ – Italy
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12 ASSESSMENT OF THE IMPACT OFA SPECIALISED
OUTPATIENT PSYCHIATRIC CLINIC ON PATIENTS
PERCEPTION OF HRQOL
Batel Marques F.J.*, Feio J.A.L.*, Alexandrino M.B.*, Silva A.M.**, Araujo A**, 
Ferreira P.L.***
Specialised outpatient psychiatric clinics deal with special groups of patients characterised by severe
forms of psychiatric disorders. Different treatment interventions are performed, outcomes being
measured by clinical evaluation. In order to asses, the potential value of humanistic evaluations as
outcome measures in the treatment process, the overall impact of interventions performed in the
psychiatric clinic on patients’ perceptions of Health-Related Quality of Life (HRQoL) was studied.
Patients attending an outpatient psychiatric clinic were invited to participate in the study. The
Portuguese version of the Sickness Impact Profile (PSIP) was administered at entry and on two
follow-up clinic visits with a 2-month period interval between clinic visits.
One hundred and four patients (72% females, median age 47 range 15-75) completed the study.
Rank scores for the PSIP dimensions at the beginning and at the end of the study are presented on
Table I
Table I
Questionnaire dimensions 1st visit 3th visit ‘p’ value*
O/A - overall PSIP scores 25.48 ± 15.37 16.51 ± 15.76 0.000
PHD - physical dimension 15.74 ± 15.52 10.61 ± 14.79 0.000
PSI) - psychological dimension 39.41 ± 22.74 26.28 ± 24.18 0.000
Independent categories
SR- sleep and rest 28.50 ± 21.45 15.46 ± 19.72 0.000
HM - home management 24.00 ± 25.39 13.59 ± 20.25 0.000
W - work 13.25 ± 22.52 9.52 ± 19.29 0.168
RP - recreation and pastime 30.58 ± 20.39 18.37 ± 20.01 0.000
E - eating 6.14 ± 7.76 3.33 ± 5.30 0.003
Students T test for paired data (*)
Improvements in patients’ perception of HRQoL were consistently found for all PSIP dimensions at
the end of the study period, providing evidence for a favourable impact of clinic interventions. This
study provided the rational to incorporate HRQoL evaluations in routine practice and evidence for
the value of measuring humanistic outcomes in psychiatric outpatients. Although being a general
HRQoL instrument, the PSIP was found to be a useful and sensible instrument in detecting
differences in perceptions of HRQoL experienced by psychiatric patients enrolled in specialised
clinics.
*School of Pharmacy,
**Sobral Cid Psychiatry Hospital
***School of Economics. University of Coimbra, Largo D. Dinis, 3000 Coimbra, Portugal, Fax no +
351 39 835139, Tel no + 351 39 834301
13 QUALITY OF LIFE IN PATIENTS WITH CHRONIC
CONDITIONS: BASELINE RESULTS FROM A
PHARMACEUTICAL CARE DEMONSTRATION PROJECT
Venturini F.*, Johnson K.A., Tannous R.E., Parker J., Kamath T., Rudolph M.
Introduction: There is increasing recognition that the impact of chronic illnesses and their
treatments must be assessed in terms of their influences on quality of life (QoL) in addition to more
traditional measures of medical outcome, such as morbidity and mortality. Consequently, measures
that address patient perceptions of their health-related well-being have been developed. Two
strategies for QoL evaluation have been described: measures that address illness-specific issues and
measures that may be used across a wide spectrum of conditions.
Objective: To describe QoL in patients with chronic conditions using both a generic and a disease-
specific QoL instrument.
Methods: Patients included in this analysis were part of a pharmaceutical care demonstration
project. In that study, patients were selected based on their prescription profile, i.e., if they were
prescribed medication for asthma, diabetes, hypertension or a combination of these. At the beginning
of the study, they received a mailed questionnaire. The questionnaire comprised questions on QoL,
satisfaction with physician services, medication adherence and personal information. The generic
QoL instrument used was the SF-36, while the disease specific instruments were: Asthma Quality of
Life Questionnaire (asthma), Diabetes Quality of Life Measure (diabetes), and the Vital Signs
Quality of Life Questionnaire (hypertension). For analysis purposes, patients were divided into five
subgroups based on their prescription profile: patients with asthma only (asthma), diabetes only
(diab), hypertension only (htn), hypertension plus diabetes (htn-diab) and hypertension plus asthma
(htn-asth).
Results: Quality of life data were available for 513 patients (54.9% female, 86.9% white, mean age
65.7 ± 14.5). The overall sample obtained a mean score of 41.3 and 54.5 in the physical component
scale (PCS) and mental component scale (MCS) of the SF-36, respectively (US population norm =
50). Diabetes specific scores were lower (i.e., the higher the score, the worse the level of QOL) than
the one found in the DCCT trial (1.97 vs. 2.1 for the satisfaction scale; 1.93 vs. 2.05 for the impact,
1.55 vs. 2.0 for the worry diabetes related), while patients in the diab group had a lower overall
diabetes QoL score than their counterparts in the htn-diab group (0.17 vs. 0.19, p=0.0 17). All disease
specific QoL scores for asthma patients (activities, symptoms, emotions, and environment) were
higher in comparison with previous research. The combination of asthma and hypertension (htn-asth)
significantly reduced the scores vs. patients with asthma only. Regarding hypertension related QoL,
all the groups (htn, htn-diab, htn-asth) had poorer scores (e.g. higher scores) when compared with
previous published research (e.g., overall score 45.9 previous studies vs. 63.8 htn, 73.4 htn-diab. 83.5
htn-asth). When compared with htn-diab and htn-asth, the htn group QoL was higher in all the
subscales.
Discussion: QoL of patients is strongly affected by their chronic conditions. Patients with multiple
chronic conditions exhibited a lower QoL than patients with just one chronic disease. In spite of the
fact that the population under study is quite elderly, the scores on mental component scale of the SF-
36 rank higher than those for the general US population. Further analysis needs to be done,
correlating disease severity and patient characteristics to QoL information.
University of Southem California, School of Pharmacy, Dept. of Phannaceutical Economics &
Policy, 1540 E.Alcazar Street. CHP 140. Los Angeles, CA 90033, USA
14 A DISEASE MANAGEMENT STUDY IN PATIENTS WITH
RESECTED COLON CANCER
A. Messori* S. Trippoli* A.M. Grion**, M.C. Giron**
A multicentre study was started to evaluate the outcome and the use of resources in patients with
resected Stage III or Stage IV colon cancer. The study was designed as a prospective and
observational collection of clinical and economic data. Patients are enrolled in the study at the time of
surgery and are followed-up for 24 months. The project involves a total of 60 Italian hospitals and
will be closed when the target number of patients is reached (250 patients).
The main objective of the study is to provide a pattern of clinical and economic information on this
disease condition and to correlate the clinical outcome data with the use of resources. The clinical
end-points measured during the follow-up of the patients include survival, quality adjusted survival,
cancer recurrence, treatment-related side-effects. The economic end-points include hospitalisation,
chemotherapy, visits, and outpatient drug prescription. The number of clinical and economic end-
points has been kept as low as possible to facilitate the completeness of data collection.
The study is ongoing. An interim analysis of the results will be carried out in September 1998.
* Laboratorio SIFO di Fannacoeconomia. c/o Centro Informazione Farmaci, U.O. Farmacia I,
Azienda Ospedaliera Careggi, Viale Morgagni 85. 50134 Firenze, Italy
** Servizio Farmaceutico, Azienda ULSS 16 del Veneto, Via Berchet 10, 35131 Padova. Italy
15 COST-EFFECTIVENESS OF GEMCITABINE AS FIRST-LINE
THERAPY FOR PATIENTS WITH ADVANCED PANCREAS
CANCER
S. Trippoli*, A. Messori*, E. Tendi**
Background: Gemcitabine is a new anticancer drug that has recently been proposed for the treatment
of advanced pancreas cancer. The therapy with gemcitabine has been reported to confer a survival
advantage it comparison with fluorouracil. Since gemcitabine is expensive. we estimated the cost per
life-year gained using gemcitabine for this clinical indication. 
Methods: The clinical material utilised in our analysis was derived from a randomised clinical trial1
in which the survival of patients receiving gemcitabine was compared with that of patients receiving
fluorouracil. To obtain an estimate of effectiveness, the survival curves published in the trial were
analysed using the Gompertz methodology. Gemcitabine acquisition cost was based on wholesale
price in Italy, in the UK and in the U.S. The overall cost of treatment is presently being estimated by
collecting individual data on the use of resources and morbidity costs. 
Results: The analysis of the survival curves showed that the mean survival of patients treated with
gemcitabine was 6.29 months, while the corresponding value for patients receiving standard
treatment was 3.20 months (both values include discounting at an annual rate of 3%). The survival
gain for the gemcitabine group was 2.9 months per patient. Our analysis of cost data for these two
treatments is in progress, but preliminary data show that the incremental cost is less than $20,000 per
patient.
Conclusions: In pancreatic cancer, gemcitabine determines a survival gain of approximately 3
months. Its cost-effectiveness profile seems so be within acceptable values.
1. Burris HA. Moore MJ, Andersen J. Green MR et al. Improvements in survival and clinical benefit
with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized
trial. J Clin Oncol 1997:15:2403-13.
* Laboratorio SIFO di Farmacoeconomia Centro Informazione Farmazi, U.O. Farmacia 1, Azienda
Ospedaliera Careggi, Viale Morgagni 85, 50134 Florence Italy.
** U.O. Farmacia 1, Azienda Ospedaliera Careggi, Viale Morgagni 85, 50134 Florence, Italy.
16 COST-EFFECTIVENESS ANALYSIS OF HIGH-DOSE
CHEMOTHERAPY WITH HEMATOPOIETIC RESCUE AS
PRIMARY TREATMENT FOR METASTATIC BREAST CANCER
S. Moriconi*, M. Puliti** V.Viviani**, S. Trippoli*, A. Messori*, E. Tendi**
Background: The analysis of published survival curves can be used as the basis for conducting cost-
effectiveness analyses in which two treatments are compared in terms of cost per life year saved. In
patients with metastatic breast cancer, high-dose chemotherapy (HDC) with autologous bone marrow
transplantation (ABMT) has been reported to improve survival in comparison with control patients
who receive standard chemotherapy1.
Methods: An incremental cost-effectiveness analysis was undertaken in which the Gompertz model
was used to determine a lifetime estimate of patient-years gained by subjects given HDC with
hematopoietic rescue in comparison with controls. Our study utilised the clinical data reported by
Bezwoda et al1 This randomised clinical trial involved 45 patients subjected to HDC with ABMT and
45 controls given chemotherapy.
Results: Lifetime survival advantage for patients of HDC wills ABMT group was estimated as 72.5
discounted patient-years for every 100 patients. The use of HDC with ABMT, as opposed to standard
chemotherapy, was found to imply an incremental cost of about $55.000 per discounted life year
gained.
Discussion: The cost-effectiveness ratio of high-dose chemotherapy with autologous bone marrow
transplantation in patients with metastatic breast cancer is borderline if one considers that acceptable
figures of cost per life year gained are generally below $50.000.
1. Bezwoda WR. Soymour L. Dansey RD et al High-dose chemotherapy with hematopoietic rescue
as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995: 13
:2483-89.
* Laboratorio SIFO di Farmacoeconomia, c/o Centro Informazione Farmaci, U.O. Farmacia 1,
Azienda Ospedaliera Careggi, Viale Morgagni 85, 50134 Florence, Italy.
** U.O. Farmacia 1, Azienda Ospedaliera Careggi. Viale Morgagni 85, 50134 Florence, Italy.
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17 QUALITYASSURANCE AND EVIDENCE-BASED DRUG
PRESCRIBING
J.P. Kampmann, S.A. Gunnarsdottir, B. Krølner, J. Meile
Unit of Rational Pharmacotherapy, Copenhagen Health Service, Sjaellandsgade 40, DK2200
Copenhagen N, Denmark
Introduction: The Copenhagen Unit of Rational Pharmacotherapy was established in 1993 as a
response to ever increasing drug costs far in excess of inflation. The Unit is staffed with a clinical
pharmacologist, 2 part-time general practitioners (GPs), a pharmacist and a secretary.
*Methods: In 1993 the Unit offered an intensive intervention program of 2 personal visits to almost
all of the 300 GPs in Copenhagen, 2 small-group meetings with clinical pharmacological teaching
and a quarterly newsletter with personalised prescription statistics. The intervention programme was
based upon a thorough clinical pharmaceutical and pharmacological examination of the most rational
and evidence-based drug treatment. In 1994 to 1996 the intervention was limited to educational
meetings and quarterly newsletters. The impact on drug prescribing habits was evaluated by drug
consumption statistics for each GP: prescribing of individual drugs in DKR, DDD and the costs of
DDD.
Results: The implementation of such a programme changed the pattern of drug prescribing amongst
GPs. Drug reimbursement in Copenhagen was considerably reduced compared to the rest of the
country and the drugs used were often more rational. The effect was most pronounced during the
personal visits, but maintained in the following years. Since 1993 the increase in drug costs in
Copenhagen has been less than half that of the other 15 counties of Denmark.
Conclusion: It is possible with an intensive programme of rational and evidence-based drug
prescription to save costs maintaining the same level of drug treatment. A randomised study with
various intervention methods is currently in progress.
18 REMIFENTANIL Vs FENTANYLA POLISPECIALISTICAL
ECONOMICAL / CLINICAL TRIAL
B. Rebesco, P. Della Casa **, M.E. Amalfitano*
Remifentanil (RE) is a new opioid with a very rapid kinetic. From an economic point of view, this
drug costs about twice fentanyl (FE), the opioid presently in use, and its short effect (about 3 min)
might increase significantly delivered doses. In our public health system, with limited resources,
before introducing a new drug in PTO a careful evaluation of the economic impact on hospital budget
must be carried out.
In collaboration with anaesthesiology dpt. a quick and predictive method like a poll was set up to
determinate the economic impact due to the delivery of (RE) instead of (FE) in every general
anaesthesia. Clinical effects produced were evaluated. Clinical and economic effects of (RE) have
been compared with (FE) holding usual anaesthesiologic technical procedures (propofol or
thiopentone. isoflurane, N2O-O2 and muscle relaxing drugs). Evaluation has been performed in 11 on
54 surgery beds chosen according to disciplines, accepting as randomised 165 (97 ISO+FE,
45M/52F), (68 ISO+RE 31M/37F) patients scheduled along 10 days of routine surgery procedures;
(FE) was used in the first five days and (RE) in the remaining ones. Requested data were synthesised
in 5 forms and collected: base data about patient, kind of surgical procedure,(RE)-(lSO) delivering
time, adverse effects, estubation and discharge time, assessment of recovery all delivered drug and
doses. Data were computerised for mathematics and statistic elaboration. Variation of the anaesthesia
cost in the (RE) group was of (+) USD 2,5 for opioid and (-) USD 0,8 for halogenate anaesthetic,
there were no significantly differences of N2O-O2 consumption. Therefore we may say that despite to
a greater cost, (RE) improves anaesthesia quality thanks to faster awakes times, shorter permanence
in surgical theatre and better recovery quality.
Finally, excluding surgical procedure in which the suitable pharmacological characteristic of
cardiovascular stability induced by the drug is strictly indicated, pharmacoeconomic evaluation
suggests (RE) use in elective surgery with a large number of surgical procedure such as day surgery ,
short -medium elective surgery and diagnostic invasive procedure.
* Pharmacy Service, S. Martino Hospital. L.go Rosanna Benzi 10, 16132 , Genova, Italy
** Anaesthesiology and Reanimation Institute, University of Genoa, L.go R.Benzi 10, 16132,
Genova, Italy
19 PRESCRIBING PATTERNS AND COST OFANTIMICROBIAL
SURGICAL PROPHYLAXIS IN ITALY
C. N. Venanzi*, C. Spoltore*, F. Venturini*, R. Di Virgilio**, M. Romero*
Introduction: Antibiotic prophylaxis is a controversial topic usually characterised by a gap between
recommended treatments and clinical practice. Clinical pharmacists should play an active role in
developing measures so rationalise antibiotic treatments and reduce cost. Knowledge of the actual
pattern of drug use is essential for planning specific interventions.
Aim: A survey was undertaken in a sample of Italian hospitals to identify a cluster of inpatients
treated for surgical prophylaxis and to describe the pattern of drug use in terms of antibiotic used,
duration of treatment, overall and daily therapy cost.
Methods: All patients treated with a course of parenteral antibiotic therapy during 4 index days in
June 1997 in a sample of 82 hospitals were surveyed. Data were collected on 2200 patients including
patients demographics, clinical and therapeutic information during hospitalisation. This analysis is
focused on usage of antibiotic treatment as surgical prophylaxis.
Results: Preliminary results are available for 800 patients (34.3% of the overall sample). Patients
were for 53% male with a mean age of 52 years (range 0-89 years). 275 (34.4%) were taking
antibiotics for surgical prophylaxis only, 368 (46%) for therapy only, 75 (9.4%) for medical
prophylaxis only, while the remaining 10.2% for a combination of reasons. The mean length of
antibiotics course for surgical prophylaxis was 4.9 days (median: 3 days) markedly shorter than for
any other reason, but with a very wide range, from 1 to 63 days. The antibiotic usage was as
monotherapy in 243 patients (88,3%), whereas a combination of  2 or 3 different antibiotics were
used to treat the remaining patients. Overall, 30 different antibiotics were used to prevent surgery
infection in 275 patients. The main drugs used were: cefazoline (16.8%). piperacilline (9.5%),
ampicilline (7.9%), cefotetan (7.0%), ceftizoxime (7.0%,) and cefotaxime (4.8%). These six
antibiotics accounted for 53% of patients treated for surgical prophylaxis. The average overall cost
and the mean cost per day (± SD) of antibiotic courses were $ 125 ± 203 ad $22 + 17, respectively.
Discussion and conclusion: Questionable practices include delaying chemoprophylaxis or
unnecessarily extending it, as well as using not recommended antibiotics as first line prophylaxis.
Several previous studies have shown that these kinds of practice are not only less effective, but also
more risky for the patients and more expensive for the health care service. Control measures should
be implemented using a multidisciplinary approach where clinical pharmacist should have an
important active role. Although these data are preliminary, they suggest that further improving
prescribing intervention in surgical prophylaxis can be found.
* Centro Studi SIFO, Consorzio Mario Negri Sud, Santa Maria Imbaro (chieti), Italy
** Direzione Medica, wyeth-Lederle, Aprilia, Italy
20 DEFINITION OF GUIDELINES FOR OFF-LABELLED USE OF
INTRAVENOUS IMMUNOGLOBULINS AT VERONA HOSPITAL
FIRM
T. Cassani, G. Scroccaro
Introduction: The Therapeutic Committee (P&T) of Verona Hospital Firm, constituted of a general
hospital (about 1.400 beds) and of an university hospital (about 900 beds), was established in 1977 to
rationalise the use of drugs within the hospital. The Secretariat has been committed from the
beginning to the university hospital Pharmacy Service and it avails itself of the collaboration of the
Drug Information Centre (DIC) of the Pharmacy.
Objectives and methods: The aim of this study is to describe, through the analysis of the
collaboration between P&T, DIC and physicians, the path followed to get to the definition of
Guidelines for use of intravenous immunoglobulins (IVIG) at the Verona Hospital Firm.
Results: The P&T Secretariat has analysed the IVIG consumption within the Verona Hospital Firm:
at the general hospital the IVIG expenditure from 1995 to 1997 has remained unchanged, while at the
university hospital it has constantly increased. The consumption of IVIG in 1995 was of 18.583 g, in
1996 of 25.535 g and in 1997 of 32.734, equal to an expenditure of £. 93.847.197 in 1995, of  £.
107.897.466 in 1996 and of £. 303.170.650 in 1997. The analysis of consumption for each
department of the university hospital has allowed the identification of the main consumers, which
are: Haematology, Rheumatology, Neurology and Paediatric wards.
The reasons for using IVIG have been identified through the analysis of justified requests and it was
verified that at the university hospital IVIG are used both for labelled and off-labelled indications and
for those not approved by P&T.
A literature evaluation was therefore made (Medline 1991-1997) and, following in particular a
consensus statement published in JAMA 1995, vol. 273, no 23, it was possible to establish that the
indications labelled in Italy and those approved by P&T are too restrictive while on the other hand, at
university hospital IVIG are requested also for indication not supported by published evidence. At
this regard, ESCP members of France and Spain, who provided us with extensive material, offered an
important contribution. P&T has therefore constitute a panel of experts representative of departments
mainly concerned, with the task of drawing up a list of indications which have been assigned the
following evaluations: A- IVIG use is recommended; B – IVIG use is recommended only in selected
cases; C - evidence does not support IVIG use. Finally, after analysis of cases in which there was
discordance between the evaluation of the panel and the published evidence, P&T approved the
Guidelines.
Conclusions: The definition of Guidelines by P&T is part of a strategy aimed at the development of a
correct use of drugs within hospital.
A successive analysis of consumption and justified requests are planned to verify the impact of this
kind of intervention on medical practice at this regard.
Department of Pharmacy - Azienda Ospedaliera ‘Intituti Ospitalieri di Verona’ - Italy
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21 IS THE PRESCRIPTION OF TICLOPIDINE IN U.S.L 7 OF
CHIVASSO EVIDENCE-BASED?
R. Corgnati, L. Poggio, C. Pietraru
Ticlopidine is a platelet aggregation inhibitor that may be useful in the prevention of thromboembolic
disorders, cardiovascular mortality, stroke, myocardial infarction and vaso-occlusive peripheral
arterial disorders. Ticlopidine may also be useful in maintaining graft patency or access sites for
hemodialysis. As ticlopidine is associated with a risk of neutropenia/agranulocytosis, which may be
life-threatening, it should be reserved for patients who are intolerant to aspirin therapy, if indicated,
The recommended adult dose of ticlopidine is 500 milligrams daily given in two divided doses; doses
of 750 milligrams daily (given in three divided doses) have also proved to be effective. With the new
National Drug Formulary which came into effect on January 1, 1994, Italian doctors can prescribe
ticlopidine within the National Health Service only by filling a special form with some information
about patient, diagnosis and pharmacological treatment and sending it to U.S.L., where is kept a
pathology register. A study of the use of current best evidence in making decision about the
prescription of ticlopidine was carried out by examining general practitioners’ registration forms
come to U.S.L. 7 of Chivasso until April 15, 1998.
533 patients received treatment with ticlopidine: 317 were males with a mean age of 66±10 years and
216 were females with a mean age of 69±11 years. Reported pathologies were: intolerance to aspirin
in cardiovascular prevention 138 (83 males - mean age 64,93±10,10 y. - and 55 females -mean age
68,62±9,47 y.); intolerance to aspirin in cerebrovascular prevention 74 (36 males - mean age
72,36±7.39 y. - and 38 females - mean age 71,16±13,45 y.); intolerance to aspirin in obstructive
peripheral vascular disease 27 (25 males - mean age 66,16±9,62 y. - and 2 females -mean age
62.50±17,50 y.); intolerance to aspirin and other diagnosis 40 (21 males - mean age 62.14±12,11 y. .
and 19 females - mean age 69,21±9,67 y.); intolerance to aspirin and diagnosis not specified 153 (93
males - mean age 64,46±10,53 y. - and 60 females - mean age 69,80±9,07 y.); coronary stenting 8 (3
males - mean age 56.67±7,36 y. - and 5 females - mean age 65,40±12,16 y.); cardiovascular
prevention without indication of intolerance to aspirin 20 (18 males - mean age 60.89±6,35 y. - and 2
females - mean age 78,00±15,00 y.): cerebrovascular prevention without indication of intolerance to
aspirin 13 (6 males - mean age 70.67±10,92 y. - and 7 females - mean age 69,86±10,44 y.);
obstructive peripheral vascular disease without indication of intolerance to aspirin 9 (6 males - mean
age 75,67±7,04 y. - and 3 females - mean age 77,33±8,99 y.): other diagnosis without indication of
intolerance to aspirin 51(26 males - mean age 65,58±9,78 y. - and 25 females - mean age
66,36±13,93 y.). The dosage of ticlopidine employed were: 125 mg daily in 2 patients (0,38%), 250
mg daily in 444 patients (83.30%), 500 mg daily in 85 patients (15.94%), 750mg daily in 1 patient
(0,19%); other dosages in 1 patient (0.19%).
This study shows that for 17,45% of patients receiving ticlopidine, doctors didn’t indicate intolerance
to aspirin therapy and for 28,70% they omitted to specify pathology. Only 16.13% of treated patients
received an affective dose of oral ticlopidine. Additional research is needed to determine non
specified diagnosis and to investigate if patients have regular blood tests done when they first start
taking ticlopidine. Programs of information to general practitioners seem to be necessary to promote
a better integration of their individual clinical expertise with the best available external evidence
from systematic research in making decision about the care of individual patients.
U.O.A.Farmaceutica Territoriale A.S.L. 7 Chivasso, via Po 11, 10034 Chivasso (TO) Italy.
22 CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA:
PHARMACEUTICAL COST IDENTIFICATION ANALYSIS OF
FRALLE 93 STUDY
L. Gauthier*, J. Delorme*, R. Gilli*, G. Michel**, D. Braguer*
FRALLE 93 is the major protocol treatment for childhood Acute Lymphoblastic Leukemia (ALL),
managed by the «Societe Francaise d’Oncologie Pediatrique» in a prospective multicenter study.
From 01/95 to 12/97, 101 patients were included in the paediatric hematological unit of our
University Hospital. They were enrolled according to their recurrence prognostic in 3 groups A, B
and C for low, intermediate and high risk respectively. They were randomised in a methotrexate
(MTX) low dose versus high dose subgroup (group A and B) and combined with idarubicin (IDR) or
daunorubicin (DNR) in group B. Anticancer and antiinfectious drugs represent $ 34,000 (40%) and $
27.000 (32%) respectively of the pharmaceutical cost of this protocol. The incidence of infectious
risk was identified as the second cost variation factor after anticancer drugs.
Objectives: Evaluate and compare pharmaceutical costs of childhood ALL in the different subgroups
of  FRALLE 93 study.
Patients and methods: This prospective analysis was conducted on 52 patients for which the follow
up was complete. Tight collaboration between clinical and pharmaceutical teams allowed to combine
clinical information, protocol of chemotherapy and antiinfectious drugs administered. To calculate
pharmaceutical cost according to hospital prices we previously developed a Microsoft Access®
database « ONCOLOGY a. (J. DELORME et al. An approach to understanding the increase in
oncology therapy use. In G. Scroccaro et al Ed. Progress in clinical Pharmacy Clinical trials and
pharmaco-epidemiology. European Society of Clinical Pharmacy. 1994. Agrigento
Results: Mean pharmaceutical cost per patient was correlated with recurrence prognostic ($ 1,060. $
2,166 and $ 5,752 for group A, B, C respectively). Moreover. the frequency of infections was linked
with the intensity of the chemotherapy (from 24 % to 60%). However, antiinfectious drug costs were
statistically increased in IDR subgroup ($ 786 versus $ 231) associated with prolonged aplastic
period. Actually, there is one relapse in daunorubicin and one in idarubicin group.
Conclusions: 1/ For MTX high/low dose randomisation, mean pharmaceutical costs were correlated
with anticancer drugs. 2/ For IDR/DNR randomisation, mean pharmaceutical costs were correlated
with anticancer and antiinfectious drugs, because of hematological toxicity of IDR. 3/ Idarubicin is a
recognised drug in childhood ALL; however response rate comparative studies between DNR and
IDR are in progress. A longer follow up is necessary to compare disease free survival and to perform
a complete cost efficacy analysis.
* Service Pharmacie Enfants. 
** Service d’ Hematologie Pediatrique. CHU Timone, Assistance Publique Hopitaux de Marseille.
264 rue Saint Pierre, 13385 Marseille Cedex 05,  France
23 CURRENT MANAGEMENT OF COLORECTAL CARCINOMA
M.C. Giron, A.M. Grion, A.C. Palozzo, B.L. Zamengo
Colorectal cancer is one of the most common visceral cancer in U.S., in both incidence and fatality
rate, as described in literature1’2. A current management cohort study is ongoing to evaluate the
incidence, the fatality rate, the therapeutical trends, the number and days and costs of hospitalisation,
the prescription coats of the out-patients in the ULSS, (Local Health District), n. 16 of Veneto
Region.
Between 1991 and 1998, 312 patients, (139 males and 173 females) were diagnosed of colorectal
tumor, with a mean value of hospitalised patients around 10 per 100.000 people per year and an
overall cost of over 20,000 million Lira. In most cases 70,8% patients were hospitalised once, the
20,2% was hospitalised twice and the rest 9% at least three times or more. Up to January 1997, 179
patients (83 males and 96 females) were still alive: among them 11 were less than 50 years old, 72
were 51-70 years old and 96 older than 70. The percentage of survivors was 52,4%, 62,1% and
94,8% respectively, in the three groups of age. For better studying the characteristics of outpatients
who had a previous hospitalisation for colorectal cancer, a one year period was chosen: during 1997,
42 patients were hospitalised for diagnosis of colorectal carcinoma, of them 34 patients were
hospitalised only one time and the rest at least two or three times. The prescriptions of these
outpatients by their general practitioners didn’t show any specific therapeutical trend beside that they
received mainly gastrointestinal system and pain-killer drugs. The several and different types of
prescribed drugs doesn’t let the opportunity to find out a drug based therapy to identify outpatients
with colorectal carcinoma.
N.Engl.J.M. 1991; 34: 709-715.
N.Engl.J.M. 1994; 16: 1136-1141.
Servizio Farmaceutico Azienda ULSS 16, Regione Veneto, Via Berchet 10, 35131 Padova, Italy
24 DIGOXIN USE IN CONGESTIVE HEART FAILURE:
PHARMACOEPIDEMIOLOGICAL STUDY
A.M. Grion, M.C. Giron, A.C. Palozzo, B.L. Zamengo
Congestive heart failure (CHF) is a major cause of morbidity and mortality in the U.S. and its
prevalence is increasing, particularly among the elderly. CHF is diagnosed in 10% of the population
by age of 75 and is the most common reason for hospitalisation in patients over 65 years of age1 . The
rising incidence may be attributed to improved survival among acute myocardial infarction patients
and to the ageing population. Since both these trends are likely to continue, CHF is becoming an
important health problem. A pharmacoepidemiological study was performed to investigate the
prevalence of CHF in the USSL n. 16 (Local Health District) of Veneto Region, Patients were
identified on the basis of:
1. cardiac glycosides prescriptions as therapeutical drug by itself or combined with other
cardiovascular drugs, such as ACE inhibitors, diuretics,nitrates, inotropic agents etc.;
2. rate of hospitalisation for CHF.
Over a period of one year (1996), in our community a total number of 11.322 outpatients (2.9% of
total population) were treated with digoxin by itself or associated with other drugs. Among them
1.399 were less than 64 years old, 4.672 were between 65-79 years old, ad 5.251 were equal or over
80 years old, In the past two years (1995 and 1996), only 1.030 patients (9,1% of the 11.322 patients)
have been hospitalised for CHF: the prevalence of hospitalisation increased with age, (6.7%, 7.7%
and 10.9% in the three groups, respectively), and it was higher in males than in females, (9.8% vs
8.7%). The number of hospitalised people per year was similar and accounted for an annual estimated
cost of nearly 7,300 million Lira.
From these data digoxin seems to be over prescribed compared to the number of hospitalisations ad
the prescribed drugs, all included in the National Formulary, for the expected patients with CHF,
accounted for more than 1,000 million Lira per year.
1. Clin.Cardiol. 1993; 16: 380-390
Servizio Farmaceutico, Azienda ULSS 16 del Veneto, Via Berchet 10, 35131 Padova, Italy
25 LICENSED DRUGS IN THE TREATMENT OF CHILDHOOD
FEVER IN ITALY
A. Addis, P. Vivarelli, M. Bonati
Introduction: In paediatric practice, drug prescribing often does not comply with an evidence based
medicine approach. As fever is a common illness in childhood, antipyretic drug use is widespread.
The objective of our study was to investigate how many and which types of antipyretic drugs are
labelled for use in children in Italy.
Methods: All antipyretic drugs marketed in Italy were identified according to the Anatomical
Therapeutic Chemical Classification index (N02B ad M01B). Indications and dosages have been
retrieved using the Italian Directory of Medicines and Manufacturers.
Results: For 13 antipyretic molecules, we found 104 trade names and 211 different formulations.
After the exclusion of all compounds with multiple ingredients (29% of all formulations), we
identified 73 (49%) formulations with no indication for use in children, 26 (17%) contraindicated and
50 (34%) formulations with dosage indications for infants or children. Four antipyretic agents
(ibuprofen, naproxen, diclofenac, propifenazone) have no formulations with labels for use in children
in Italy. Antipyretic which are not commonly used for children elsewhere (e.g., nimesulide), are
marketed with a indication for paediatric use.
Discussion: Our analysis shows how antipyretic drugs commonly used in other countries have no
indications for use in childhood in Italy (e.g., ibuprofen). A large number of formulations of
antipyretic drugs are not licensed or have no indications for use children. In Italy it is cause for
concern that the licensing authority and pharmaceutical companies have not evaluated antipyretic
drugs that are used extensively in children.
Conclusion: Pharmaceutical companies, pharmacists, prescribers and regulatory authorities should
work together to improve pharmaceutical care in children.
Regional Drug Information (C.R.I.F.), Laboratory for Mother and Child Health, Istituto di Ricerche
Farmacologiche “Mario Negri”’ Milano, Italy
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26 BREAST OVER BOTTLE: THE CONFLICT OF INTERESTS
P. Vivarelli*, M. Brunetti**, A. Addis*, M. Bonati*
Introduction: The benefits of human milk over artificial formulas may persist beyond infancy, and
are clearly established and widely recognised in both the industrialised and developing world. The
duration of breastfeeding remains short regardless of whether the WHO international code for
marketing breast milk substitutes is adopted or not, raising some economic considerations.
Methods: In Italy we reviewed the official 1998 National Therapeutic Formulary for registered
infant milk formulas, manufacturers and prices.
Results: Thirteen manufacturers market 144 preparations with 74 brand names (111 ad 71
respectively for powdered milk). Taking into account the most widely used (ad registered)
substitutes, we focused our analysis on starting (38) and carry on (27) powdered formula “for all
babies”. Size of preparations range from 200-2000 g for both types (median 550 and 700 g,
respectively), whereas the price was higher for starting (37-67 Ital. Lire/g; median 58; 1 UK
pound=2,784 Ital. Lire) than carry-on formulas (26-60 Ital. Lire/g; median 48). A linear relationship
was found between price and size of formula preparation but it is important to underline that
comparable packs (for contents and amount) showed a average variation in price of 10 Ital. Lire/g,
corresponding to 4,000-20,000 Ital. Lire/pack.
Discussion: To quantify the effect of those differences on family economies, we use regression
analysis and age related nutritional milk needs  (from 2.43 kg during the first month of life to 2.17
kg/month after the fifth) to estimate the cost of formula feeding a infant in the first year of life.
Estimates range from 1.04-1.62 million Ital. Lire depending on whether one uses the 200 g or 2 kg
package. Since the average monthly income of an Italian family is 3.5 million Ital. Lire, and half this
for 20% of families, at least 3-5% of the net family income may be necessary to feed an infant with
formula. Taking that the Italian incidence of live-born babies as 530,000/year it is straightforward to
calculate that the national expenditure for “standard” (not soy, premature, anti-reflux, etc.) formula
may range from 553 to 857x109 Ital. Lire, once again depending on the package size.
Conclusions: Permanent education and recall efforts for the population - including physicians -
could raise the incidence and duration of breastfeeding, and oppose initiatives by infant formula
manufacturers that regularly breach the code. Manufacturers’ interests conflict with those of the
majority of mothers and their children, and the cost of purchasing formula can be presented as a
further saving and a convincing tactic for promotion breastfeeding,
* Laboratory for Mother ad Child Health, Istituto di Ricerche Farmacologiche “Mario Negri”, Via
Eritrea 62, 20157 Milano, Italy.
** Laboratory of Health Services Research.
27 SHORT VERSUS LONG THERM PROPHYLAXIS WITH
CEFTAZIDIME IN PATIENTS WITH SURGICAL
COLECISTECTOMY: CLINICALAND PHARMACOECONOMIC
OUTCOMES
G. Liuzzo, F. Saglimbene, M. Castiglione
The prophylaxis treatment in antibiotic therapy is very reality on the basis of clinical and economic
reasons.
The objective of this study was to evaluated two groups of patients with two prophylaxis regimens:
Short therm versus Long therm prophylaxis - STP vs/ LTP - from clinical and economic point of
view.
38 patients with surgical colecistectomy were randomised 1:1 to STP or LTP with ceftazidime 1 gr.
im administred 1 hour before surgical intervention, 5 and 12 hrs. after, in STP group, versus 1 gr. im
bid for each day during the follow up on surgery, in LTP group. The following outcomes were
evaluated:
- days necessary for the medication;
- score of surgical wound;
- temperature;
- hospital recovery days;
- number of days who the physicians were involved;
- number of days who the nurses were involved;
- economic outcomes: costs of two treatments regarding the use of ceftazidime;
The two treatments show statistical similar results of:
- number of days necessary for the medication;
- score of surgical days;
- temperature;
- statistical important different results about:
- number of recovery days: 104 in STP vs/ 174 in LTP;
- costs of pharmacological treatment with ceftazidime: group in STP:400 $ for each patient; group
in LW; 2.500 $ for each patient (+ 710 %).
Conclusion: The treatment with ceftazidime 1 gr. im in STP in patients with surgical colecistectomy
is greater advantageous than in LTP, from clinical and economic point of view - + 70 % of recovery
days in LTP vs. STP ; + 710 % of direct costs of pharmacological treatment with ceftazidime in LTP
vs. STP.
Similar outcomes on the two treatments:
- score of surgical wound;
- temperature;
- number of days who physicians and nurses ware involved.
28 THE ARNO PROJECT: A POPULATION ORIENTED DATA BASE
FOR DRUG UTILIZATION IN ITALY
M. de Rosa*, G. Tognoni**
For ARNO working group
Introduction: Since 1988, we set up a system with the purpose of collecting and monitoring data on
drug prescriptions by providing advanced computer and informatics resources to the Local Health
Units,
Objectives: The system has been activated with the purpose of providing a friendly and efficient
interface between a “core facility”, where data are concentrated and a powerful elaboration capacity
is assured, and the Local Health structures where the data of General Practitioner’s prescriptions are
collected for reimbursement, in order to build a comprehensive drug utilisation Data Base.
Materials and methods: The system has been conceived to combine an highly sophisticated central
computational capacity, which allows all types of handling and statistical analyses of the huge masses
of data derived not only from the database on prescription, but from many databases linked together
(population, vital statistics health and social indicators, drugs information, to implement a flexible
system that enables to analyse the data from different point of view. The system, monthly updated, is
distributed through the network (Internet) and the authorised users can access to the database. A
working group with the co-ordination of the Cineca-Inter university Computing Center has been
establish to co-ordinate the collaboration of the Local Health Units, the Italian Society of Hospital
Pharmacy (SIFO), and the Laboratories of Clinical Pharmacology and Epidemiology of the Istituto di
Ricerche Farmacologiche Mario Negro. The main strength of the Arno project is its
“epidemiological” orientation. Many efforts have been made with Date Quality to have a reliable
population oriented database which assures a high degree of confidence to both general and stratified
analyses. The drug utilisation data are expressed as number of Defined Daily Doses (DDD), boxes
and expenditure related to 1000 inhabitants.
Results: The main findings of the first general, will be used to document the methodological stenght
of this large Data Base which allows the real-time monitor of 4 millions inhabitants - 20 millions of
prescriptions - 16 Local Health Units of North Italy, during year 1997, as they are prescribed by 3500
General Practitioners and 400 Paediatricians.
Specific attention is been given to the variability of the prescriptions patterns across gender and age
strata
Conclusions and perspectives: A comprehensive database of drug prescriptions can be seen as an
important point of departure for exploration of new area of epidemiological research (case control
studies, chronic cohorts), and development of surveillance projects.
* CINECA - Vie Magnanelli 6/3 40033 Casalecchio (BO) Italy
** 1st. Mario Negri V.1e Eritrea 20157 Milano Italy
29 DIABETES MELLITUS PHARMACOEPIDEMIOLOGY
APPROACH TO COMPLICATIONS THROUGH CASE-
CONTROL METHODOLOGY
A. Ferrarese*, M. De Rosa**, G. Monesi***, G. Tognoni****
Introduction: The Arno Data Base which includes prescriptions in general practice, has been used to
provide a pharmacoepidemiology profile on treatment of diabetes in routine conditions of care. The
study is based on a protocol by a group of Diabetologists who wanted to improve care practice thanks
to an interdisciplinary and clinical epidemiological approach (GIVID).
Objectives: 1. To assess the prevalence of drug-treated diabetes, through the identification of the
patients treated with Insulin and Oral Antidiabetics; 2. To analyse concurrent treatments such as
indicators of comorbidity and diabetic pathology complications; 3. To produce data to implement
programs for continuing education for both Diabetologists and General Practitioners.
Materials and methods: The study includes the population of 9 Local Health Units of Veneto in the
North-East of Italy (1,873,827 inhabitants) participating to the ARNO Project who received
prescription medications free of charge, as part of the national Health care program (SSN), during
1996. The cohort of patients were identified by prescriptions for insulin and oral antidiabetica (more
than 4 boxes/year). The selection of controls to examine the concurrent therapies (meant to check
Diabetes complications) was done under the design of a “case control” study, controls were identified
among the patients who had taken Antiabetic drugs; their number was twice the number of cases,
with same gender, age, and general practitioner. Statistical analyses was performed to compare the
proportions of patients with and without diabetics. The drug utilisation data are expressed as number
of defined daily doses (DDD), related to 1,000 patients.
Results: A population of 40.439 patients was recruited, it shows a prevalence of drug-treated
Diabetes of 2.2%. The 86.6% of patients is treated with Oral Antidiabetic (alone or together with
insuline) while the 13.4% is treated with insuline only, consistently with the expected portions of
NIDDM and IDDM. From the analysis of the concurrent therapies in the 40-64 year-old class, these
results come out:
• The consumption of Cardiovascular agents (which show micro and macroangiopathic
complications) is double in diabetics patients (especially for ACE-inhibitors, Calcium channel
blockers and Diuretics which cover about 60% of the whole area, while Beta blocking agents are
equally prescribed among cases and controls).
• Diabetic women are prescribed total a higher amount of drugs than men (171,923 DDD/1000
patients vs. 152,138) and a higher exposure to drugs for cardiovascular problems.
• A comparison with the female control population shows a higher exposure of diabetic women to
Psychotropic drugs and a considerably lower consumption use of Sexual Hormones.
Conclusions and perspectives: Drug utilisation data can contribute to describe the epidemiology of
drug-treated diabetes and its complications in a real caring context, and can promote dialogue
between Diabetic Centers and Primary Health Care Services. In this sense, the cooperative
(multidisciplinary) use of available data-base can lead to:
• Identify cohorts of patients depending from each Family Doctor to start local working groups;
• Carry out population studies especially aimed at critical patients;
• Complete drug exposure data with test strips consumption, in order to study the self-monitoring
compliance.
These date can represent an useful interface with Public Authorities and Patients’ Associations for
defining health care strategy and planning activities.
* Farmacia Ospedaliera - Osp. Civile 45100 Rovigo Italy, 
** CINECA - Via Magnanelli 6/3 40033 Casalecchio (BO) Italy, 
*** Diabetologia - Osp. Civile 45100 Rovigo Italy, 
**** 1st Mario Negro V.1e Eritren 20157 Milano Italy.
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30 UPDATING THE NATIONAL LIST OF REIMBURSED DRUGS
(NLRD) IN AN ERA OF LIMITED RESOURCES
S. Shani, S.H. Klang, B. Haran, J. Shemer
The National Health Insurance Law was implemented in Israel in 1995. The law states that each
citizen is entitled to receive health care treatments of established quality. The NLRD was defined as
the 1994 formulary of the largest sick fund in Israel. All drugs included in this list must be reimbursed
by the different sick funds. From 1995 to 1997, the NLRD was updated only once since the Ministry
of Finance allocated no financial resources for this purpose, although numerous new molecules have
been registered. The Pharmacoeconomics Unit in the Pharmaceutical Administration at the Ministry
of Health set up a mechanism for updating the NLRD by evaluating clinical, epidemiological and
economic data. Every six months, the Pharmacoeconomics Unit screens all the new registered drugs
in that lime period for breakthrough products. Breakthrough products are drugs with significant
clinical efficacy compared to current therapies for the same disease-state, or drugs which are
indicated for the treatment of diseases for which no drug therapy is currently available. The
Pharmacoeconomics Unit then sets priorities according to the available clinical data from the
literature together with applications from physicians politicians and patients’ interest groups.
Subsequently, the number of potential users for each drug is estimated, and an economic evaluation is
made: A cost minimisation analysis is carried out in order to assess the coat of including each drug in
the NLRD. For selected drugs at the top of the proposed list, a cost benefit analysis is carried out in
order to determine the money saving potential. The above procedure leads to the creation of a list of
drugs considered for inclusion in the NLRD ranked according to their clinical and economic
performance. When a certain budget is allocated for updating the NLRD, the decision-maker uses the
proposed list as a basis for deciding which drugs will be included in the NLRD. In December 1997,
after a considerable public outcry, the Ministry of Finance allocated NIS 150 million for updating the
NLRD, Since the proposed list was existent, the Minister of Health was able to sign the order for the
addition of several drugs to the NLRD within a week.
Ministry of Health, Jerusalem, Israel.
31 A SYSTEMATIC APPROACH TO NEW DRUG
DEVELOPMENTS: MONITORING THE USE OF THE ATYPICAL
ANTIPSYCHOTIC OLANZAPINE
A. Gilchrist *, M. Taylor **, K. Drury, P. Murray
The emergence of a new range of psychotropic drugs, which carry both significant clinical and cost
implications, presents a challenge to mental health care. Evidence based practice implies that
objective rational information should ideally govern prescribing. Edinburgh Healthcare Trust
identified the need for a systematic evaluation of new drugs. Olanzapine is one of several new
psychotropic drugs with potentially significant cost implications due to its widespread use.
This study armed to implement a systematic evaluation of olanzapine prescribing and impact within
the Trust. The objectives were to identify the population for whom olanzapine was selected, and
monitor treatment outcome to influence future prescribing of olanzapine.
A newly devised standardised assessment instrument which included demographic and clinical items
was completed by the prescribing clinician following a structured decision to initiate olanzapine. The
newly devised clinical assessment instrument used a linear analogue scale with referenced anchor
points and included the clinical global impression scale, as well as an estimate of the positive and
negative symptoms of schizophrenia, adverse events and quality of life. The inter-rater reliability of
this scale will be demonstrated. After six months of treatment each patient on olanzapine will be
reviewed by the same prescribing clinician using the same clinical assessment instrument in order to
determine if any change has occurred.
Preliminary results at baseline are reported here. 42 patients initiated on olanzapine therapy have
been recruited and assessed from 5 January to 20 May 1998 (age range = 16-69 years). Patients
comprised: acute psychiatry inpatients, 19; outpatients, 18; learning disabilities, 2; old age
psychiatry, 2; continuing care inpatients, 1. Starting dose of olanzapine ranged from 5 to 25mg daily.
22 patients were initiated on 10mg daily (= recommended starting dose). Reasons for initiating
olanzapine therapy as indicated in the structured patient assessment represent some of the patient
selection criteria as follows: 7 patients had experienced intolerable extrapyramidal side effects from
traditional antipsychotic drugs; 6 had schizophrenia in whom minimising side effects from the outset
of treatment was a priority; 1 had marked negative symptoms; 6 had refractory schizophrenia; 3 for
other reasons; 17 had a combination of 2 of these reasons and 2 had a combination of 3 of these
reasons. Ideally, atypical antipsychotics should not be prescribed concurrently with other
antipsychotics. 14 patients were also receiving other antipsychotic medicines. 11 were receiving one
other antipsychotic, 2 were receiving 2 others and 1 was receiving 3 others.
The efficacy of the new antipsychotics such as olanzapine has been established in worldwide trials.
However the issue of cost efficiency remains to be settled. Evaluation of therapy in clinical practice
using this method will provide a locally valid perspective on patterns of use, including monotherapy
versus polypharmacy, efficacy and tolerability. It will enable future prescribing of the drug to be
based on the evidence of continuously generated local data.
*Department of Pharmacy & ** Department of Psychiatry, Edinburgh Healthcare Trust, Royal
Edinburgh Hospital, Edinburgh EH1O 5HF, Lothian Pharmacy Practice Unit/University of
Strathclyde, UK.
POSTER DISCUSSION FORUMS
1 EFFICACYAND SAFETY OF SERTRALINE VERSUS
CLOMIPRAMINE IN PATIENTS WITH MODERATE TO
SEVERE DEPRESSION: A RANDOMISED, OPEN LABEL,
PARALLELGROUP, CONTROLLED CLINICAL TRIAL
F. Batel Marques*, A. Vaz Serra,**, N. Cobrado*, M.M. Caramona*
Purpose: to comparatively evaluate the efficacy and safety of sertraline and clomipramine in patients
with moderate to severe depression.
Methods: A multi-centre, randomised, open label, parallel-group, comparative study of sertraline
with clomipramine was conducted in psychiatric outpatients. Male and female patients aged between
18 and 65 years with the diagnosis of moderate to severe major depression according to DSM-III
criteria and a score ‡ 18 in the first 17 items of the HAM/D (Hamilton rating scale for depression)
were recruited. Follow-up evaluations were performed at 2, 4 and 8 weeks. Initial daily doses of 50
mg of both sertraline and clomipramine were administered. Efficacy was comparatively evaluated by
changes in HAM/D and CGI (clinical global impression) scores while outcome measures for safety
included frequency of side effects and number of dropouts due to adverse drug effects. Statistical
analysis was carried out using parametric and non-parametric tests according to the study protocol.
Significance for differences was set at 0.05 level.
Results: 119 patients were recruited and randomised (58 on the sertraline group and 61 on the
clomipramine group). There were no significant differences on baseline scores for the HAM/D and
CGI. At the end of the study HAM/D scores decreased 66% for the sertraline group and 55% for the
clomipramine group (p<0.05). Similarly CGI scores decreased 58% and 46% for the sertraline and
clomipramine groups, respectively (p<0.05). Dropouts due to side-effects were 11 in the
clomipramine group and 4 in the sertraline group (p>0.05). A total of 27 patients in the sertraline
group experienced, at least, one side effect, while side effects were present in 46 patients of the
clomipramine group (p<0.05).
Discussion and conclusions: The present study confirmed the better safety profile of sertraline when
compared to clomipramine for the selected indications, which is consistent with previous trials.
However, differences in efficacy were not documented. This results provided evidence for a more
favourable efficacy profile of sertraline in managing patients with moderate to severe depression,
when compared with clomipramine,
This study was supported by a research grant from Pfizer Portugal.
* Laboratory of Pharmacology School of Pharmacy,
** Department and Psychiatry University Hospital and School of Medicine, Largo de D. Diniz, 3000
Coimbra Portugal. Fax No + 351 39835139, Tel no + 351 39834301
2 ONLY HALF OF PATIENTS FREE OF GASTRIC ANTI-
SECRETORY DRUGS AFTER HELICOBACTER PYLORI
ERADICATION TREATMENT
H-F. Kwint*/***, P.A.G.M. De Smet**/***, L.G. Biesma***, J. Riezebos***, 
S.E.B. Werkman***, B.M.E.R. Steffens***
Introduction: Treatment strategies aimed at eradicating Helicobacter pylon have shown positive
results in the management of duodenal ulcer disease and gastritis. Triple- and quadruple-regimens
lead to cure rates of 85 to 95 % in randomised clinical trials. Whether these rates can be extended to
patients treated in general clinical practice remains to be verified. Not all these patients will have
confirmed disease. Because of the side effects of the different regimens drug compliance in general
practice could also be less.
Aim: This study investigates the use of anti-secretory drugs 6 to 12 months after Helicobacter
eradication treatment as an indirect indicator for success of the treatment.
Method: In a retroprospective study the use of gastric anti-secretory drugs six to twelve months after
Helicobacter treatment was assessed. In 4 different community pharmacies 105 patients were
selected which received Helicobacter eradication treatment between April 1995 and April 1997. The
medication histories of these patients were analysed.
Results: Only 46 % of the patients was free of anti-secretory drugs six to twelve months after
Helicobacter treatment. 25 % incidentally (< 0.5 dose unit a day) used anti-secretory drugs and 29 %
did this chronically (>0.5 dose unit a day).
Discussion: The low ‘cure rate’ in comparison with randomised controlled trials may be attributable
to different factors. Firstly, it has to be established whether Helicobacter was successfully eradicated
in the patients using incidentally or chronically anti-secretory drugs 6 tot 12 months after treatment.
For example, lack of medication compliance of Helicobacter treatment could cause unsuccessful
eradication. Secondly, indication of anti-secretory drugs before and after treatment has to be asked.
Eradication helps prevent ulcer recurrence in patients with duodenal or gastric ulcers but its value is
less clear with other causes of dyspepsia. Also gastric complaints could have a different character
after treatment. To answer these questions questionnaires of the patients using anti-secretory drugs 6
to 12 months after Helicobacter treatment will be send to their general practitioners. At the moment a
randomised clinical trial is carried out in 15 community pharmacies to assess if extensive information
and motivation by the pharmacist of patients with Helicobacter treatment can improve medication
compliance and reduce use of anti-secretory drugs 6 to 12 months after treatment.
Conclusion: This study shows that Helicobacter pylori eradication treatment lead to only 46 %
patients free of gastric anti-secretory drugs 6 to 12 months after treatment.
* Stevenshof institute for Research, Theda Mansholtstraat 5b 2331 JE Leiden, The Netherlands, 
E-mail: sir@stevenshof.nl (correspondence),
** Scientific Institute Dutch Pharmacists, KNMP, The Hague
*** SIR Pharmacy Practice Masterclass
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3 NEPHROTOXICITY OFAMPHOTERICIN B IN LIPID
EMULSION: A RANDOMISED, CONTROLLED STUDY IN
NEUTROPENIC PATIENTS
A.l. Martinez*, A. Novo**, F. Puigventos*, O. Delgado*, J. Bargay**. J. Gines*, M.V. Alvarez*,
J. Besalduch**, J. Serra*
Objectives: To evaluate the differences in renal tolerance to amphotericin B administered in 5%
dextrose in water [group A] compared to amphotericin B administered in a lipid emulsion (Intralipid
20 %®) [group B].
Methods: Prospective, controlled, randomised, open study comparing the two treatments protocols
in 20 haematological neutropenic patients with fever of unknown origin despite empiric antibiotic
therapy. All patients start amphotericin B at 10-20 mg/24h and the doses was increased in a few days
to 0,5 mg/Kg/24h. During treatment we registered serum creatinine, serum urea, potassium
supplements and concomitant nephrotoxic drugs administered.
Results: 9 patient were included in group A and 11 in group B. No differences in initial serum urea
and creatinine and in duration of concomitant nephrotoxic drugs administered were detected. The
comparison of initial versus final serum creatinine in group A (0,86 mg/dL vs 0,97 mg/dL) and in
group B (1,03 mg/dL vs 1,33 mg/dL) didn’t presented statistical differences. Also no differences in
the initial versus final serum urea, in the potassium supplements and in the efficacy of the treatment
were observed.
Discussion: Five clinical trials comparing both modalities of amphotericin B administration,
concluded that amphotericin B in Intralipid was less nephrotoxicity than control. The day doses
administered to our patients (0,5mg/Kg/day), lower than mentioned studies (range 0,71-1,31
mg/kg/day) could explain the results.
Conclusions: At the doses of 0,5 mg/Kg/day, the administration of amphotericin B presented good
renal tolerance in both groups. No differences were observed in the parameters of renal function of
patients treated with amphotericin B in lipid emulsion and in dextrose 5 % in water.
* Pharmacy Department, 
** Haematology Department. Son Dureta Hospital. C/Andrea Doria 55, 07014-Palma de Mallorca,
Balearic Island, Spain
4 COST-BENEFIT ANALYSIS OFA NATIONWIDE INFANT
IMMUNISATION PROGRAMME AGAINST HEPATITIS A IN AN
AREA OF INTERMEDIATE ENDEMICITY
G.M. Ginsberg, P.E. Slater*, D. Shouval**
The availability of safe and effective Hepatitis A vaccines prompts an evaluation of a nationwide
infant vaccination campaign as a supplement to strategies aimed at specific at-risk groups such as
travellers and military personnel. This paper estimates the costs and benefits for a nationwide infant
immunisation programme against Hepatitis A for the period from 1997 - 2014 in Israel, an area of
intermediate endemicity. The model is also extended to provide estimates of benefit-cost ratios a
selection of other countries covering a wide range of endemicity levels. A policy of aiming to
immunise all one year olds in Israel from 1997—2014 would for a cost of $61.9 million (plus $20
million in terms of lost work and transport costs) to the health services and $83.9 million to society,
reduce the number of cases of Hepatitis A during the next 45 years from 505,000 to 223,000. This
would reduce national expenditures by $128.4 million in health service resources alone, $84.2
million in averted work absences and transport costs in addition to a further $22.4 million in averted
premature mortality costs. The health service, direct benefit and social benefit to cost ratios are
2.07/1, 2.53/1 and 2.80/1 respectively.
The adoption of a nationwide infant HAV immunisation policy in Israel appears to be not only
medically but also economically justifiable.
Medical Technology Assessment Division and
* Department of Epidemiology Ministry of Health, Ben Tbai 2, Jerusalem, Israel. 
** Liver Unit, Hadassah Hospital, Ein Kerem, Jerusalem, Israel.
5 EVIDENCE BASED PHARMACEUTICAL CARE OF
HYPERTENSIONE: AN ITALIAN EXPERIMENT
E. Marrazzo, L. Ferraro*
Introduction: The pharmaceutical expenditure of Azienda U.S.L 1 (Local Health Office 1) of Turin
for 1997 was approximately 67 billion lire, 25% of which (17 billion lire) goes to pharmaceuticals for
treating hypertension. Considering the prevalence of hypertension in the adult population and the
incidence of antihypertensives on the total expenditure for pharmaceuticals it has been decided to use
the compulsory training courses, which the Azienda U.S.L. 1 has been holding for General
Practitioners (GPs) for years. This decision was made based on the need to promote a more rational
use of these drugs in order to control hypertension according to the international guidelines.
Objective: The objective of this paper is to evaluate to what degree a training program can modify
the prescription-writing profiles of the doctors involved, is order to plan, if necessary, further
initiatives.
Materials and methods: The course was broken down into three sessions attended by 78 GPs, 34%
of the doctors under contract with the Azienda U.S.L. 1 (232), During the course various problems
related so hypertension were discussed: the proper way to measure blood pressure, diagnosing
hypertension, drug and nondrug therapy. etc. Moreover, a pharmacist gave a lecture illustrating data
on the prescription and cost of antihypertensives. All the prescriptions written by the 78 GPs who had
participated in the course for the previous and subsequent months were analysed and divided in
therapeutic groups following ATC classification: C02 Antihypertensives, C03 Diuretics, C07 Beta
blocking agents, C08 Calcium channel blockers, C09 Agents acting on the renin-angiotensin system.
Comparisons were made: 1) among therapeutic groups and 2) among single active principles. The
indicators used were: the number of pieces prescribed and their price.
Results: At present the preliminary results for the two months (March and November 1997) are
available. The cost of antihypertensives in both months made op 23% of the total. The therapeutic
groups most used were the same for both months: C09 Agents acting on the renin-angiotensin system
(— 42% of the total number of pieces and —50% of the total expenditure for that category) and CO8
Calcium channel blockers, (- 28% of the total number of pieces and —31% of the expenditure in that
category) in conflict with the provisions of the guidelines. Nonetheless, in November 1997, the
prescription of beta blocking agents (+ 2%) and diuretics (+ 7%) were higher than in March 1997.
The prescriptions for ACE-inhibitors (+ 5%) and calcium channel blockers (+ 1%) also increased,
though to a leaner degree. Using the same methodology and indicators, all the single active
principles, divided into therapeutic groups, were taken into consideration. The largest number of
prescriptions were written for enalapril and enalapril + hydrochlorothiazide. Losartan, a drug brought
onto the market in 1997, is increasing in the number of pieces prescribed by approximately 30%.
Conclusions: Though a few positive signs can be seen by this preliminary analysis of only two
months (more prescriptions of diuretics and beta blocking agents), it should be considered that what
occurs in two months is not indicative of the yearly trend of a phenomenon. Moreover, for a chronic
pathology such as hypertension, it is probable that the adoption of the guidelines reflects the
acceptance of new patients assigned to doctors, rather than a change in therapies already established
and perhaps well tolerated. We shall see if the outcome of the other months confirms these
preliminary results.
Drug information Centre, Azienda USL 1 Torino, Via S. Francesco da Paola 31, 10123 Torino, Italy
* U.O.A. Farmaceutica Territoriale ASL 4 Torino, Lungodora Savona 26, 10152 Torino, Italy
6 INTRAVENOUS IMMUNOGLOBULIN USE
Vallès R., Gorchs M., Garcia M.
Introduction: In recent years, the usage at intravenous immunoglobulin (IVIG) has increased
progressively. IVIG are labelled in Spain for use in various primary immunodeficiencies HIV
infection during childhood, multiple myeloma, chronic lymphocytic leukemia, bone marrow
transplantation, idopathic thrombocytopenic purpura, Kawasaki syndrome and Guillan - Barre
syndrome. Furthermore, their efficacy in dermatomyositis, multifocal motor neuropathy and chronic
inflamatory demyelinating polyneuropathy has been established in controlled clinical trials.
However, the information available on other uses, such as Lambert - Eaton myasthenic syndrome and
myasthenia gravis, is provided only by preliminary results from controlled studies, open-label trials
and case reports and the response was variable. With this wide range of indications and because IVIG
area a very expensive product of human plasma, we thought it necessary to review the use of IVIG
and the evidences supporting their efficacy.
Aim: The objective of this study was to analyse the use of IVIG in our hospital and to evaluate if the
indications were supported by the medical literature.
Methods: The indications, dosage and data of the patients who received IVIG from April 1997 to
March 1998 were collected. We also reviewed the information available on the indications and
efficacy of IVIG.
Results: Seventy-five patients were treated with IVIG during the study period. Of the patients, forty-
seven were children with a mean age of 5,43 years (min. o and max. 24 years) and the indications
were primary immunodeficiencies (24 patiens/47: 51%), HIV infection (17/47: 36%), and the other
six patients had neonatal sepsis, lymphoblastic leukemia, idiopathic thrombocytopenic purpura,
Guillain-Barre syndrome. Kawasaki syndrome and nephrotic syndrome. The adults patients, with a
mean age of 55.5 years (min. 23 and max. 82 years), received IVIG for: primary immunodeficiencies
(8/28: 28.5%), idiopathic thrombocytopenic purpura (7/28: 25%), chronic demyelinating neuropathy
(4/28: 14.3%), and other indications, one case each, were dermatomyositis chronic lymphocytic
leukemia, immunoblastic lymphoma, myasthenia gravis, multiple myeloma, polymyositis, Lambert-
Eaton myasthenic syndrome, Guillain-Barre syndrome and pure red cell aplasia.
Conclusion: Only in the case of nephrotic syndrome evidence did not support IVIG use, but the
efficacy in some other indications has not been established in controlled clinical trials.
Department of Pharmacy, Corporacio Sanitaria del Parc Taulli, Parc Tauli s/n, 08208 Sabadell, Spain
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7 PREVALENCE AND NATURE OF SELF-MEDICATION
REQUESTS IN COMMUNITY PHARMACIES OF CENTRAL
PORTUGAL
F. Batel Marques, N. Cabrado, M. Caramona
Self-medication is a component of the individual management of the health/disease process and must
not be neglected as an important part of community pharmacy practice. The recently approved
European guideline on the switching procedure of the legal status of medicinal products for human
use, from prescription to non-prescription, clearly points out the role of community pharmacists as
important advisers in promoting responsible self-medication.
This study was aimed at characterising the prevalence and the nature of self-medication related
requests in community pharmacies.
A cross-sectional study in 21 community pharmacies (10 typically urban, 11 typically rural) located
within the Portuguese Central Health Authority area was carried out during one complete working
day at each pharmacy. According to the study protocol requests for pharmacy services were classified
in “self-medication requests” and “non-self-medication requests”. Self-medication requests were
typified, according to their nature, as the acquisition of medicines without medical prescription
(products not classified as medicines for human use were not included in this study) and not asking
for any advice, or the presentation of signals/symptoms and/or requesting any advice from pharmacy
personal. Statistical analysis was produced by using Chi-square (to compare prevalence),
significance for dependencies being set at a 5% level. Results are, whenever applicable, expressed as
mean ± S.D.
A total of 2053 clients (1369 - 66.7% - from urban pharmacies) were identified during the study
period, corresponding to an average of 98 ± 65 clients per day and per pharmacy (137 ± 58 in urban
pharmacies). Self-medication requests were present in 33% and in 29% of the clients attending urban
and rural pharmacies, respectively (p>0.05). Of a total of 649 self-medication related requests, 580
(89%) were made by the straight acquisition of a medicinal product without asking for any advice,
whilst in 69 (11%) of the cases any advice was requested. The last represented 9.7% of self-
medication related requests in urban pharmacies and 12.7% in rural pharmacies (p>0.05).
Self-medication was found to represent nearly one third of the motives for requesting community
pharmacy services regardless of the socio-geographical location therefore being a generalised
phenomenon across the society. The vast majority of requests corresponded to the acquisition of self-
selected medicines without asking for pharmacist’s advice. This was the case in both urban and rural
pharmacies. For community pharmacy practice these results strongly suggest the need for a more
active intervention if the safe use of non-prescription medicines and responsible self-medication
habits are to be promoted. Moreover, and in the light of a high prevalence of self-medication attitudes
amongst pharmacy clients, professional interventions seem to be of potential favourable impact in
maintaining and promoting public health.
This study was supported by a research grant from Novartis Consumer Health, Portugal.
The authors very much acknowledge the collaboration of the pharmacists and pharmacy technicians
involved, without which this study would not had been possible.
Laboratory of Pharmacology, School of  Pharmacy, University of Coimbra, Largo de D. Diniz, 3000
Coimbra, Portugal. Fax: +351 39835139, Tel: +351 39834301
8 GUIDELINES POLICIES AND PROCEDURES FOR HANDLING
CYTOTOXIC DRUGS IN THE PHARMACY
E. Mizrahi
The vast number of cytotoxic agents in use today and the ever increasing number of
chemotherapeutic protocols created the need for the use of a handy, concise, and a guiding directive
to assist the pharmacists in performing their tasks.
In order to facilitate the acquisition of regularly needed information by the pharmacists who practice
in the cytotoxic unit and to establish a uniform practice within the unit, guidelines for practice were
written.
The commonly used cytotoxic agents in the medical center were addressed as to their storage,
reconstitution, dilution, expiration dates, maximal doses, and their use within the context of the
commonly used protocols in the medical center. Guidelines for safety, for doing various tasks, and for
the work flow in the pharmacy cytotoxic unit were established and written down to assist and direct
the pharmacists and the pharmacy technicians perform in a safe, easily achieved, and a uniform
manner. These guidelines have been helping the practising pharmacy staff in the cytotoxic unit of
Sheba Medical Center in Israel, and are presented as a suggested guidelines model.
These guidelines writing task was part of the pharmacist work and was made possible by the
pharmacy director who realised the need for the compilation of the data and allocated the time for its
development.
Department of pharmacy, Cytotoxic unit, Sheba Medical Center, Ramat Gan, Israel
9 GENTAMICIN KINETIC PROFILE OF NEONATES IN AN
INTENSIVE CARE UNIT
Rocha M.J., Almeida A.M., Leitao F., Santos J., Falcao A.C., Caramona M.M.
Gentamicin is an aminoglycoside antibiotic frequently used to treat gram-negative bacillary
infections and suspected sepsis in neonates. Obstetrical risk factors and disease procedures required
for the management of critically ill neonates are associated with an increased risk of infections.
Although dosage schedules have been established for premature and term infants, in order to obtain
appropriate gentamicin serum concentrations, toxic levels are common in this age group. The risk of
toxicity or poor efficacy is further increased because of the wide inter-patient variability in the
pharmacokinetic parameters of gentamicin, depending on the stage of maturity of the new born. The
aim of the present work was to assess the gentamicin kinetic profile in these patients in order to
improve our specific dosage regimens. The study involved 40 infants of 31.4±4.9 weeks of age
(mean±SD), weighing 1.7±1.0 kg and treated with standard doses of gentamicin (3.8±1.2
mg/kg/day). All of them presented two gentamicin concentrations (peak and trough levels) obtained
as part of the clinical routine procedure of our intensive care unit. Demographic and clinical data
were retrospectively collected in the sequence of the existing protocol that was implemented in order
to prevent toxic and/or sub-therapeutic gentamicin concentrations. The kinetic analysis was done
assuming a one-compartmental open model with zero-order absorption (IV perfusion) and first-order
elimination. The pharmacokinetic parameters determination was done by nonlinear regression
performed with the most popular clinical pharmacokinetic software package used in our country PKS
®, Abbon Diagnostics). The obtained results showed the final estimates for both clearance (CL =
0.59±0.26; CV = 45%) and volume of distribution (Vd = 0.40±0.10; CV = 26%). Bearing in mind the
demographic characteristics, the obtained estimates for CL and Vd seemed to be similar to those
described by other authors. This observation is relevant for us in order to allow better “a priori” and
“a posteriori” dosage schedules and could be used to develop the clinical pharmacokinetics service
implementation in our hospital. Finally, this information must be complemented by the fact that
trough levels above 2 µg/mL (potentially toxic concentrations) were observed in 45.5% of our study
population, which can be changed in the future by the clinical application of our work.
Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, 3000 Coimbra, Portugal.
E-mail: acfalcao@cygnus.ci.uc.pt
10 THEOPHYLLINE, STEROIDS AND GOLD: AN ANTIASTHMA
PHARMACOKINETIC COCKTAIL
Falcão A.C., Rocha M.J., Castel-Branco M.M., Mano A.J., Almeida A.M., Caramona M.M.
Theophylhine has been used for several decades in the treatment of asthma and remains the most
widely prescribed antiasthma drug worldwide. In recent years, however, with the appreciation of the
importance of inflammation in the pathogenesia of asthma and the consequent use of therapeutic
alternatives (mainly the steroids and ß2-agonists), the use of theophylhine in industrialised countries
has declined. Nevertheless, long term administration of oral corticosteroids in patients with asthma
may be associated with serious side effects and non-steroidal antiinflammatory drugs, including gold
salts, have been shown to reduce the need for systemic corticosteroid treatment. In the present work
we studied the kinetic profile of theophylhine administered concomitantly with methylprednisolone
(steroid compound) and auranofin (oral gold) by analysing the relationship between doses and
observed and predicted concentrations of theophylhine in six adult patients. The kinetic analysis was
done by using two different commercial software packages, the PKS (Abbott Diagnostics) and the
CAPCIL (SIMKIN Inc./courtesy of Dade-Behring), assuming a one-compartment open model with
first-order absorption (ka for PKS=0.5 h-1; Ka for CAPCIL=O.3 h-1) and first-order elimination (CL,
t1/2 and V4 by default for each program). The measured and predicted theophylhine concentrations
were used to calculate percentage prediction errors:
%PE = [(predicted conc. — measured conc.)/measured conc.] x 100
A linear regression analysis was also carried out for the observed concentrations and those predicted
by each method (PKS versus CAPCIL). The obtained results showed a bias in the observed versus
predicted concentrations indicating persistent over-predicted theophylhine levels (results expressed
as median and interquartile range; %PE for PKS = 56.9 [36.8-114.5]; %PE for CAPCIL = 32.6 [14.1-
91.2]). The regression analysis between observed versus predicted concentrations confirm the same
tendency showing an intercept significantly different from zero for both cases (PKS and CAPCIL).
Additionally, it must be emphasised that all serum theophylhine concentrations were positioned
below the accepted therapeutic window for this drug (10-20 mg/L). In conclusion: 1) both PKS and
CAPCIL fail to predict the theophylhine concentrations based exclusively on their population
pharmacokinetic parameters by default; 2) theophylline concentrations were lower than expected
with obvious implications on its efficacy and emphasised the importance of therapeutic drug
monitoring for this kind of drug/patients; 3) we can speculate about a possible interaction between
theophylline and auranofin because the decrease in theophylline concentrations was greater than that
supposed by the concomitant steroid utilisation (plus 25% on theophylhine clearance).
Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, 3000 Coimbra, Portugal. 
E-mail: acfalcao@cygnus.ci.uc.pt
Supported by Programme PRAXIS XXI (PRAXIS/PSAU/P/SAU/0136/96)
abstracts 1 99  09-06-1999 15:18  Pagina A15
Pharmacy World & Science
Volume 21 Nr. 1A 1999
A16
11 PHARMACOKINETICS OF CYCLOSPORINE A IN PAEDIATRIC
PATIENTS
J. Cardenete, M.A. Marngues*. R. Tomas, R. Moreira, I.  Badell**, M. Torrent**, J. Bonal
The objective of the study was to analyse the pharmacokinetic behaviour of cyclosporine A (CPA) in
paediatric patients undergoing allogeneic bone marrow transplantation (BMT) and to evaluate the
utility of a pharmacokinetic study performed before bone marrow infusion. The pharmacokinetic
study was used to individualise the CPA dosage in order to achieve therapeutic levels as soon as
possible.
The study population consisted of 35 consecutive hematology patients scheduled for an allogeneic
BMT between September 1991 and February 1998. Ten days before BMT a single IV CPA dose of
3mg/Kg was given to the patients over a 2h infusion. Eight blood samples were collected from each
patient. Whole-blood CPA levels were determined by specific fluorescence polarisation inmunoassay
(TDx®). For the pharmacokinetic characterisation, a two-compartment open model was fitted to the
concentration-time data of each patient by nonlinear regression analysis (Adapt PC collection). This
information was used to design the individual CPA dosage.
The desired CPA trough levels were 100-200 ng/mL.
Results:
Age (years) ID(mg/Kg/d) Vc(L/Kg) CI(L/h/Kg) T1/2ß(h)
7±4 6.0±2.0 0.886±0.593 0.557±0.262 3.8±3.8
ID:IV initial dose;Vc:volume of distribution (central compartment); Cl:clearance; T1/2ß:Beta half
life.
An important interindividual variability was found in all pharmacokinetic parameters. The highest
variability was observed in half-life, having a coefficient of variation of 100%. There was an inverse
relationship between age and CPA clearance. Consequently, the younger children have higher CPA
dosage requirements. The pharmacokinetic study performed before BMT worked well in predicting
the individual CPA requirements. Most of the patients achieved levels within the therapeutic range 24
h after starting the recommended ID.
* Department of pharmacy, Hospital de Sant Pau, Sant Antoni MaClaret, 167,06025, Barcelona,
Spain.
** Department of paediatric, Hospital de Sant Pau, Sant Antoni Ma Claret, 167.08025, Barcelona,
Spain.
12 TWO SAMPLES AUC ESTIMATION FOR MONITORING
CYCLOSPORIN-A (CsA) FOLLOWING KIDNEYAND BONE
MARROW TRANSPLANT
M.E. Araujo-Pereira*, L.M. Pereira**/***, J.G. Morais***
In recent years several authors have been proposing a therapeutic drug monitoring strategy for CsA
based on the estimation of steady-state AUC with very few data points collected over a given dosing
interval. This was indeed a recommendation emerged from the 5th International Congress of
Therapeutic Drug Monitoring and Clinical Toxicology in Vancouver 1997. Those abbreviated AUC
estimates have been tested in clinical settings and seem to bring numerous advantages over a
complete, stressful and costly 8 to 10 blood samples based AUC determination. Our study expanded
this rationale to the usage of CsA in kidney (KT) and bone marrow transplanted (BMT) patients
using only two concentration-time points optimally placed in the 12 hours dosing interval. 35
patients submitted to BMT were treated with either intravenous CsA or oral CsA microemulsion
(Neoral ®), and 32 KT patients were given orally either conventional CsA or CsA microemulsion.
Totally, 84 data sets were analysed consisting of complete plasma concentrations versus time profiles
and respective AUC’s estimated either by a trapezoidal or a log-trapezoidal rule. Subsequently, a
stepwise multiple linear regression procedure was conducted using the plasma concentrations as
independent and identically distributed predictors of the previously calculated AUC’s. The goal was
to identify the least possible combination of predictors, including an independent term whenever
needed, capable of adequately estimate AUC. The necessary statistics were used to assess the
underlying assumptions, such as autocorrelation, as well the goodness of fit criteria. Typical
equations were obtained as follows,
IV Oral
KT - AUC=712+2.59 C2h + 5.38 C6h
R2=0.94
BMT AUC=-15+3.58 C2h + 7.94 C8h AUC=-9+3.19 C2h + 6.81 C6h
R2=0.97 R2=0.99
These expressions provide good predictability, are very easily implemented and reduce significantly
the waste associated with an intensive blood sampling strategy. Furthermore, in many cases through
concentrations alone are useless for CsA dosing adjustment and this methodology may essentially
with a similar effort provide a much accurate alternative.
* Servicos Farmaceuticos Hospital de Sta. Maria, Av. Egas Moniz, 1600 Lisbon, Portugal
** UFEB - Pharmacotherapy, Epidemiology and Biopharmaceutics Unit. Instituto Superior de
ciencias da Saude - Sul, Quinta da Granja, 2825 Monte de Caparica, Portugal
*** Faculdade de Farmacia Universidade de Lisboa, Av. Forcas Armadas 1600 Lisbon, Portugal
13 BOOTSTRAPING VALIDATION OF THE ABREVIATED AUC
ESTIMATION
L.M. Pereira*/***, M.E. Araujo-Pereira**, J.G. Morais***
Recently, several reports have surfaced in the literature proposing the estimation of the area under the
curve (AUC) using only a few concentration-time data points by means of multiple linear regression,
rather than using the full data set classically required by numerical integration procedures, such as the
trapezoidal rule. However, no report has been published yet validating that technique in formal
statistical terms. Being an inference problem transposed to a time series framework, a number of
underlying assumptions are implicit whether or not they are addressed by the end users. The reason
why good correlation coefficients may be encountered between three, two or even one concentrations
and the overall AUC is more of an information theory and maximum likelihood nature, than of a
regression type. Predictability is definitely a different issue than good correlation or goodness of fit.
Therefore, the objective of this study was to make use of a bootstrapping sampling technique in order
to generate equally plausible pseudo-patients and their respective steady-state drug levels. Several
data sets could thus be generated with different error structures. For each of those amplified samples
the exact AUC was calculated as well as different abbreviated
estimates obtained by stepwise multivariate linear regression. Linear models were selected on the
basis of their adjusted R2 and power statistic. Finally several matrixes resulted with the variances and
covariances for all the estimates, and bias and precision were determined for each model.
CV=5% CV=20% CV=40%
AUC2 AUC3 AUC4 AUC2 AUC3 AUC4 AUC2 AUC3 AUC4
MPE(%) 0.026 -0.06 -0.01 1.1 0.59 0.62 5.1 -2.4 1.6
RMSE(%) 4.0 4.3 4.2 9.5 6.7 6.1 45 35 27
CV=Coefficient of variation for bootstrapping seed, AUC indices=number of predictor concentration points. MPE = 
Mean prediction error, RMSE = Root mean square error
As a conclusion it became apparent that the abbreviated methodology for estimating AUC is heavily
dependent on the variability for each covariate (concentration), or in other words, the intraindividual
variability. The findings confirmed the appropriateness of the applications so far encountered in the
literature for this methodology, namely for less noisy drugs in terms of their concentration versus
time profiles, irrespective of their patient to patient variability. Also the application of the so-called
limited sampling model for the estimation of AUC’s in bioequivalence studies is subject to the same
caveats aforementioned. In all cases caution should be taken in characterising the variability patterns
of each drug, for instance using bootstrapping sampling.
* UFNEB — Pharmacotherapy, Nutrition and Biopharmaceutics Unit, Instituto Superior de Ciencias
da Saude - Sul, 
Quinta da Granja, 2825 Monte de Caparica, Portugal
** Servicos Farmaceuticos, Hospital de Sta. Maria, Av. Egas Moniz, 1600 Lisbon, Portugal
*** Faculdade de Farmacia, Universidade de Lisboa, Av. Fomas Armadas 1600 Lisbon, Portugal
14 THE EVIDENCE BASE MEDICINE AND THE LOCAL ETHICAL
COMMTITEE ACTIVITIES IN AN ITALIAN UNIVERSITY
HOSPITAL
R. Di Pasquale, M. Dell’Aera, R. Trombetta, M. Lattarulo
Introduction:. The application, assessment and analysis of controlled clinical trials and the presence
of pharmacist in the Ethical Committee delineate a new scenario where the pharmacist is increasingly
involved in clinical pharmacy activities.
Aims: 1) To assess the qualitative (study design) and quantitative aspects of clinical trials approved
in the course of two years activity by the local Ethical Committee. 2) To create a computerised
records system of the studies assessed.
Materials and methods: The data were input in a data base in which the drug studied, the disease,
the study design, the number of cases enrolled, etc. . . , were recorded for each trial.
The analyses were made using the EPIINFO program The quantitative data, i.e. frequency of studies
of given drugs and disease, were also studied. The data on the methodological quality of the studies
were obtained by cross-analysis of the experimental phases (I,II,III,IV) with the multicentre and/or
randomised nature of the trials, and use of placebo or drugs as controls.
Results: Over two years of activity, the Ethical Committee met 21 times and 186 trials were
approved: 175 experimental protocols were assessed (some protocols were presented in several
hospitals). The drug categories most studied were: antimicrobial agents (19%), followed by
cardivascular drugs (17%). The most commonly experimented drugs were the piperacillintazobactam
association, azitromycin. cefepime, picotamide and interferon beta. The diseases most studied were
hypertension (22 studies), followed by respiratory infectious (17 studies). Clinical studies were found
to be predominantly multicentric (165 of 186). Controlled, randomised trials accounted for 148
studies, vs 22 non randomised. Most studies were conducted comparing standard drugs with new
drugs (122 of 186). The study populations were mainly adults (142 studies), followed by the elderly
(24 studies) and lastly children (7 studies). The study design most frequently called for enrolment of
200 to 400 patients (79 studies). followed by 400 to 600 (42 studies).
Discussion: The data show that few new drugs were studied. Interferon beta us an exception, bearing
in mind its promising results in relapsing-remitting type multiple sclerosis. The other drug studies do
not tend to a true advancement of knowledge but rather to extensions of indications or, more often,
the study of “me-too” molecules, as shown by their use in diseases like hypertension and respiratory
infections. Overall analysis of the data points out that the study protocols are well designed and
conducted, as evinced by the data on mono/multicentric and/or randomised trials but that the
scientific utility of the data obtained in these studies is not always high.
Pharmacy Service, University Hospital of Bari, P.zza G. Cesare, 11, 701124 Bari, Italy
E-mail: farmacia@cimedoc.uniba.it
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15 DOCUMENTING PHARMACEUTICAL CARE IN COMMUNITY
PHARMACY
K. van der Graaf*, L. de Jong-van den Berg**, H. de Gier***
Introduction: Electronical documentation of Pharmaceutical Care (PC) activities has been
introduced in about 250 community pharmacies, since its introduction in 1995 (De Gier, 1996).
Management of drug related problems has become daily practice, as an integrated part of
computerised processing of patients and prescriptions by using the Pharmacon ®-system. An
evaluation of PC activities in planning practice research is needed.
Aim: The primary objective of this pilot-study was to describe the application of the Electronical
Pharmaceutical Dossier (EPD), in particular to answer the following questions:
• What procedures are being used by pharmacy staff in documenting patient consultations and
interventions?
• What are the patient characteristics of patients involved in PC documentation (risk groups,
disease oriented, any patient with drug related problem)?
• What is the response of patients to documentation of PC oriented activities in their pharmacy and
interventions based on this registration?
A secondary objective was the development of a method to analyse the EPD registrations. In other
words: how useful are structured text files and code systems in practice research?
Methods: A retrospective, descriptive evaluation of a random sample of 100 EPD’s per pharmacy
will be carried out in 10 community pharmacies. All available data, such as medication histories,
drug use profiles and registrations of drug related problems and subsequent interventions will be
analysed based on a total period of six months. Patients’ responses to interventions will be
documented based on a questionnaire survey by the pharmacists involved in the pilot-study.
Results: The feasibility of the research methods will be presented based on the evaluation of 100
EPD’s in one pharmacy during the period October 1997 - April 1998. 
Discussion: The proposed methods will be used in the 10 pharmacies in order to evaluate
documentation of PC activities in 1,000 EPD’s. After this pilot-study the research methods will be
applied in a larger survey including 25 community pharmacies and 150 general practitioners. Patients
will be recruited after the start of medication to treat asthma, migraine, hyperlipidaemia, or diabetes
mellitus type II. The collaborative use of protocols and documentation systems to achieve the
integrated care with pharmaceuticals will be compared with the ‘traditional’ practice of
pharmaceutical dispensing, in which the team approach and documentation are lacking.
* Apotheek ‘De Drie Stellingen’, P.O. Box 122, 8430 AC Oosterwolde, The Netherlands.
** Department of Social Pharmacy and Pharmacoepidemiology, Faculty of Pharmacy, University of
Groningen, 
Ant. Deusinglaan 2, 9713 AW Groningen,The Netherlands.
*** Health Base Foundation, Randhoeve 225, 3995 GA Houten, The Netherlands,
De Gier JJ. The Electronical Pharmaceutical Dossier®: an effective aid to documenting
pharmaceutical cara data. Pharm World Sci 1996;l8(6):241-3
.
16 IMPACT OFA CLINICAL PHARMACIST ON DRUG THERAPY
IN A DEPARTMENT OF INTERNAL MEDICINE
A. Hammerman, R. Rotem, N. Meidan, A. Porat
Several studies have documented the impact of clinical pharmacy services on patient care and drug
costs in hospital wards. However in Israel, where most hospitals do not provide such services, until
now it has not been tested whether they are beneficial in the local health care setting
Objectives: To determine whether a clinical pharmacist’s activity in an internal medicine department
of a medical center in Israel leads to changes in quality of drug utilisation and costs.
Methods: During the first three months of the clinical pharmacist’s work all interventions and
consultations given in the department were documented. The effect of’ these interventions on the
costs of drug therapy was calculated by measuring the change in drug acquisition costs during the
study period and during the three preceding months in this department as well as in the other five
internal medicine departments of the hospital, in which there were no clinical pharmacy services.
Results: During the study period the pharmacist joined 44 clinical rounds in which he documented
40 consultations as a response to physician requests for drug information and 42 interventions on his
own initiative. The pharmacist’s recommendations were accepted in 38 of the 42 cases (90%). In 10
cases the pharmacist’s initiative to improve the quality of drug therapy led to an increase in drug
acquisition costs. However, during the study period, the overall drug costs in the department went
down 12.6% relative to the three preceding months, while during the same period the drug costs in
she other internal medicine departments went down 2.2%.
Conclusions: The results of this study conform with many other studies that show that clinical
pharmacists have a beneficial impact on the quality of drug therapy and on cost savings in the
hospital. For these reasons, the clinical pharmacist is shown to have a crucial role in the department
medical staff.
The Soroka University medical Center, Beer Sheva, Israel.
17 DOES MONITORING OF THE DIGOXIN LEVEL SERVE AS AN
ESSENTIAL TOOL IN THE OPTIMISATION OF THERAPY?
E. Blum*, H. Mayan**, A. Hoffman*
Digoxin is a widely used medication for the treatment of supraventricular arrhythmias and congestive
heart failure. It has a narrow therapeutic-to-toxic ratio (0.8-2 ng/ml) which, if not maintained, can
lead to life-threatening adverse reactions including heart blockage, ventricular tachycardia and death.
Since many (patho)physiological factors affect digoxin blood concentration it is essential to achieve
individualised optimisation of therapy. Unfortunately, the commonly used radioimmunoassay assay
has specificity problems that make the results unreliable in certain cases. The necessity of digoxin
blood monitoring and the proper utilization of this tool were examined in a prospective study
conducted at the “Sheba Medical Center”. To assess the importance of digoxin blood levels
monitoring, the indications for ordering the assay were characterised, the cases of digoxin blood
levels above 2 ng/ml were evaluated, and the degree to which the medical staff used the results to
improve therapy were recorded and analysed. Data were collected from the medical charts of 86
patients. It was found that the assay was ordered as a routine procedure for any patient receiving
digoxin. It was clinically unnecessary in 73% of the cases!! Furthermore, in most cases (31%) the
medical staff paid no attention to the results. In characterising the cases of toxicity, it was found that
most of the toxicity cases resulted from drug interactions and/or renal insufficiency. These cases
could have been identified beforehand by a clinical pharmacist or an alert medical staff (even without
the digoxin assay). In conclusion, the outcome suggests that the medical team did not adequately use
the digoxin concentration data to optimise therapy. On the other hand, this data can be clinically
helpful when interpreted with respect to the entire clinical situation. The uncritical use of blood level
data should be avoided while an educated intervention by a clinical pharmacist can assist the medical
staff to use these assays in a rational, safe and economical manner.
* School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel.
** Dept. of Medicine E, Sheba Medical Center, Tel Hashomer. Israel.
18 EVALUATION OF THE USEFULNESS AND UTILISATION OF
DRUG INFORMATION PROVIDED TO THE CLINICIAN BY
THE DOCTORLINE SERVICE.
Mele A., Albano M., Di Pasquale R., Vasaturo T. ,Nobili A., Macaria G.L.
Introduction: Several articles concerning information in clinical practice have been recently
published. The application of Shaughnessy’s formula for evaluating the usefulness of different kinds
of information source has been evaluated in a pilot study.
Objectives: To test the applicability of this formula as a method for evaluating and rating the
usefulness of the information provided to the clinician by a medical information service
(DOCTORline).
Methods: Based on the Shaughnessy definition the usefulness of each information provided results
as follows (Usefulness of medical information = Relevance x Validity / Work): Relevance - for each
query an increasing score is attributed according to A) the frequency of the problem arising, and B)
the level of direct applicability of the information requested to an ongoing clinical case (Relevance =
A+B). Validity - for each information provided an increasing score will be attributed as a function of
the scientific value and the type of documentation used; “critical appraisal” criteria of literature
evaluation will be used. Work - an increasing score system is attributed as the product of the factors
A) time spent to produce the information; B) resources, both human and technological, utilised for
obtaining the information (Work = A x B). Each factor of the Shaughnessy formula was rated
according to a 5 point scale, the final score ranging from a minimum value of 0.2 to a maximum of
25. The formula was then tested on a sample of 80 consecutive requests for drug information
received by the DOCTORline service between July and August 1997.
Results: Mean values of relevance, validity and work were, respectively, 3.1 (± 0.8), 3.2 (± 1.3) and
3.2 (± 1.5). No correlation was found between the factors (relevance vs validity r=0. 10; relevance vs
work r=0.03; validity vs work r=-0.08). Mean value of the usefulness of information given in reply to
the 80 queries was 4.8 (± 5). 
Conclusions: Despite the limited amount of information analysed and certain problems encountered
in the standardisation of the mode of using the score system of the three formula factors, the
application of the Shaughnessy formula was found to the very useful for monitoring and controlling
the quality of a clinical information service. On there bases, at the beginning of May a new study has
been started to assess the usefulness of a larger sample (200) of queries.
References:
• Nobili A, Gebru F, Rossetti A, et al. Doctorline a private toll-free telephone medical information
service. Ann Pharmacother 1998; 32:120-5.
• Nobili A, Macario G.L., Gebru F., et al. Information lines run by doctors are useful. BMJ 1997;
314:904.
• Nobili A, Macario G.L., Tettamanti M, et al. Un metodo quantitativo di valutazione dell’utilita
delle informazioni fornite al medico da un servizio di informazione sul farmaco. Risultati di uno
studio pilota condotto dal servizio Doctorline. Giornale Italiano di Farmacologia Clinica 1998;
Vol 12 (1).
• Rossetti A, Gebru F, Nobili A, et al. The role of drug information in Doctorline a private toll-free
telephone medical information service. E.S.C.P. 4th European Conference on Drug Information.
21-23 May 1997. Amsterdam, The Netherlands.
ASFE - Associazione per lo Sviluppo della Ricerca in farmacoEpidemiologia.Viale Certosa 148 -
20156 Milan, Italy
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19 GROUP DECISION-MAKING AT THE FORMULARY
COMMITTEE: SELECTION AND ECONOMIC EVALUATION OF
MEDICAL DEVICES METHODOLOGICAL ISSUES FOR DAILY
PRACTICE
Applications using the PHARMA DECISION® software
P.A. Kenigsberg*, the Pharma Decision users group
Surprisingly, economic evaluation of medical devices has attracted little academic interest, although
expenditures for medical devices often equal drug expenditures in many hospital pharmacy budgets.
As few, if any, comparative trials are usually available, elements of information are usually limited to
a comparative analysis of technical characteristics from suppliers documentation and quantitative
needs from the care units.
In order to assess cost-effectiveness (or value for money) when comparing medical devices, a general
and simple methodology has been developed and tested with the PHARMA DECISION users group.
For many devices, it is the medical intervention, not the medical device itself, that improves health.
Therefore, we propose that effectiveness criteria for medical devices may be measured not only in the
perspective of the patient, but also in the perspective of the medical, nursing or technical staff.
Effectiveness can be assessed by using either evidence-based, technical characteristics of devices or
subjective preferences from the care unit teams. Subjective preferences will reflect expert opinion
when little evidence is available. Preference analysis, based on multi attribute utilities assessment,
will reflect the attributes of devices that appear most useful to the users in real practice. Documented
needs from the users can then be used as selection criteria by the Formularly Committee.
Evidence-based and subjective elements, cost and effectiveness remain clearly separated at all steps
of the procedure, in order to facilitate the dialogue between the pharmacist and the group of users.
A comparison of up to 10 different devices can be graphically displayed on the PHARMA
DECISION® cost-effectiveness decision matrix.
This synthetic view of all the dimensions of device evaluation facilitates group decision-making
upon mutually agreed terms.
* Manager, Operational Pharma Economics, Pharmacia & Upjohn, BP 210, F-78051 St Quentin en
Yvelines Cedex, France.
20 SAFETY OF USE FOR SINGLE-USE MEDICAL DEVICES
COLLECTION, ANALYSIS AND REPORT OF EVENTS
A 1 7-month retrospective study at Assistance Publique des Hopitaux de Marseille
M. Lambert, N. Ausias, S. Pradeau-Bernardini
Assistance Publique des Hopitaux de Marseille is a 4000-bed, teaching hospital, localised on 4
distinct sites. Expenditures for medical devices represent 50% of the total pharmacy budget (of which
20% concern single-use devices).
Rapid evolution of technologies and operating procedures is leading to increasing invasiveness of
medical devices and potential risk. In a teaching hospital where staff or students turnover is very
high, it is important to maintain a continuous information on the proper use of the 3500 active
references used in the hospital.
Since January 15th 1996, French Hospital Pharmacists have a legal obligation to declare any incident
or alteration of characteristics and / or performances of medical devices.
We have surveyed 106 device-related events over a period of 17 months. Spontaneously declared
events were collected manually on specific event report forms. The 4 different sites provided the
same contribution as to the number of declarations. Medicine provided 40% of declared events, ICU
25%, paediatrics 20%, surgery 11%. We found that most of the incidents concern the less invasive
devices (classes I and IIA as defined by EC Directive 93/42), which are the most widely used
references. Declared events originated respectively from nurses (65% of the cases) and from
physicians (30%).
As soon as an event is declared, we inform the supplier, who conducts an investigation in the
concerned hospital department. Observed causes of incidents concern faulty manufacturing in 50%
of the cases. The other 50% of incidents can be attributed to lack of information, education,
resistance to change and device misuse.
We have been using the Pharma Decision vigilance logbook for the follow—up and consolidation of
the different stages of event instruction. We found the software useful in reporting information back
to the care units. As central purchasers, we intend to use data collected in the vigilance database to
refine our device selection criteria in hospital tenders.
Assistance Publique des Hopitaux de Marseille, Department of Pharmacy, Central Purchasing
Center, 80 rue Brochier, 13354 Marseille, France.
21 HOME SERVICE PROGRAM FOR ONCOLOGY PATIENTS IN
CONTINUOS INFUSION USING ELASTOMERIC INFUSOR
M. Gambera*, I. Aiello*, D. Fagnani**, M.M. De Rosa*
A home service program for oncology patients using elastomeric infusor filled in the centralised
laboratory for oncology preparations of the hospital pharmacy department for all type of patients,
day-hospital, ambulatory and in-patients was started. The aim of the present research is to assess the
compatibility and stability of oncology therapies and to evaluate some publications on similar
experiences (1, 2, 3). The protocols used are 5-FU continuous infusion for the treatment of the colon
carcinoma or the methastatic stomach malignancies (4, 5) and VAD - Vincristine, Adriamicyn and
Desametason - for the second line treatment of multiple myeloma (6).
The results permitted to reduce hospitalisation time with improved quality of life for oncology
patients, lower coat of the treatments achieved by managing the therapy only in day-hospital giving
the same quality in terms of safety for the patients and efficacy of the treatment.
The elastomeric infusor used have proved to be easy to handle, inexpensive and able to minimize
hospitalisation for the patients. This project has strengthened the very good co-operation existing
between oncologists, pharmacists and nurses, reduced the risks for the staff and enhanced the quality
of the service offered to the community.
(1) Di Salvo L. et al. Home service using elastomeric infusors, experience of the C.F. Palermo
Center. The Italian Journal of Clinical Pharmacy 1994, 2, 8: 64-70.
(2) Moore C. Strong D. Administrative and technical support of ambulatory infusional cancer
chemotherapy (ICC). J. Infus. Chemoter. 1996 Fall, 6:4, 161-3.
(3) Schleis TG, Tice AD. Secting infusion devices for use in ambulatory care. Am. J. Health Syst.
Pharm, 1996 Apr. 13, 53:8, 868-77.
(4) Kohne et al. Eur. J. Cancer 1995: 31 A Supp.
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